Preparation and characterization of carvedilol and indomethacin amorphous solid dispersions by Duszová, Alena
 UNIVERSITY OF LJUBLJANA 
FACULTY OF PHARMACY 
 
 
 
ALENA DUSZOVÁ 
 
MASTER'S THESIS 
 
MASTER'S STUDY PROGRAMME INDUSTRIAL PHARMACY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ljubljana, 2019 
 II 
UNIVERSITY OF LJUBLJANA 
FACULTY OF PHARMACY 
 
ALENA DUSZOVÁ 
 
PREPARATION AND CHARACTERIZATION OF CARVEDILOL AND 
INDOMETHACIN AMORPHOUS SOLID DISPERSIONS 
 
PRIPRAVA IN VREDNOTENJE AMORFNIH TRDNIH DISPERZIJ 
KARVEDILOLA IN INDOMETACINA 
 
MASTER'S STUDY PROGRAMME INDUSTRIAL PHARMACY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ljubljana, 2019 
 III 
This master's thesis was performed at The Research Center Pharmaceutical Engineering 
(RCPE) in Graz, Austria at Department Area II - Advanced Products & Delivery under the 
supervision of Ass. Prof. Dr. Amrit Paudel and written at the Faculty of Pharmacy, 
University of Ljubljana, Slovenia under the supervision of Prof. Dr.h.c. Stanko Srčič, MSc 
Pharm. 
 
Acknowledgements 
I would like to express my sincere gratitude to Ass. Prof. Dr. Amrit Paudel and Prof. 
Dr.h.c. Stanko Srčič, MSc Pharm for providing me with the opportunity to perform my 
master's thesis at RCPE. I would like to thank Prof. Dr.h.c. Stanko Srčič, MSc Pharm for 
his support during the entire time I was working on this thesis. Amrit, thank you for 
sharing your knowledge about amorphous solid dispersions and helping me with the 
challenges which occurred while working on the thesis. 
 
I would like to offer my special thanks to the lab team of Area II and other members of 
RCPE with whom I was working with. All of you were very helpful, kind and taught me 
many practical things. Some of you became my friends and made my stay in Graz even 
more unforgettable. 
 
Special thanks also to Andrew, who helped me with revising the English. 
 
 
Statement 
I hereby declare that I have performed and written this master's thesis by myself under the 
supervision of Prof. Dr.h.c. Stanko Srčič, MSc Pharm and co-supervision of Ass. Prof. Dr. 
Amrit Paudel.  
 
Ljubljana, 2019 
 
Alena Duszová 
 
President of MSc thesis defence committee: Assoc. Prof. Robert Roškar, M. Pharm., Ph. D.  
Member of MSc thesis defence committee: Assist. Prof. Stane Pajk, M. Pharm., Ph. D. 
 IV 
TABLE OF CONTENTS: 
 
1. INTRODUCTION ............................................................................................................. 1 
1.1 Classification of amorphous solid dispersions ............................................................ 1 
1.2 Stability of amorphous solid dispersions ..................................................................... 3 
1.2.1 Role of polymer in amorphous solid dispersions ................................................. 3 
1.2.2 Recrystallization from amorphous state ............................................................... 5 
1.3 Relaxation .................................................................................................................... 6 
1.4 Characterization of amorphous solid dispersions ........................................................ 8 
1.5 Manufacturing of amorphous solid dispersions ........................................................ 10 
2. AIM ................................................................................................................................. 12 
3. MATERIALS AND METHODS .................................................................................... 13 
4. RESULTS AND DISCUSSION ...................................................................................... 21 
4.1 Determination of Tg values ........................................................................................ 21 
4.2 Characterization of freshly prepared ASDs (at day 0) .............................................. 26 
4.3 Stability evaluation of ASDs ..................................................................................... 41 
4.4 Temperature-dependent ATR-FTIR .......................................................................... 56 
4.5 Enthalpy relaxation .................................................................................................... 58 
5. CONCLUSION ............................................................................................................... 62 
6. REFERENCES ................................................................................................................ 64 
7. APPENDIX ..................................................................................................................... 67 
 
LIST OF FIGURES: 
 
Figure 1. Plot of thermodynamic properties against temperature. Modified from (6). ........ 2 
Figure 2. Enthalpy-temperature diagram illustrating the enthalpy relaxation of an 
amorphous system (a), reheating the system (b) and enthalpy recovery (c). Ta is the 
annealing temperature. Modified from (18). ................................................................. 7 
Figure 3. Structure of carvedilol. Adapted from (28). ........................................................ 13 
Figure 4. Structure of indomethacin. Adapted from (28). .................................................. 13 
Figure 5. Structure of HPMC-AS. Adapted from (30). ...................................................... 14 
 V 
Figure 6. Structure of Eudragit® L100-55. Modified from (32). ....................................... 14 
Figure 7. Tg values of Carvedilol:HPMC-AS mixtures showing decreasing Tg values with 
increasing mixture drug content. Tg value have been obtained by mDSC. ................. 22 
Figure 8. Comparison of Carvedilol:HPMC-AS Tg values obtained from film-casted 
method (blue line) and calculated theoretical values (orange line). ............................ 22 
Figure 9. Tg values of Indomethacin:HPMC-AS mixtures illustrating decreasing Tg values 
with increasing mixture drug content. Tg value have been obtained by mDSC. ......... 23 
Figure 10. Comparison of Indomethacin:HPMC-AS Tg values obtained from film-casted 
method (blue line) and calculated theoretical values (orange line). ............................ 24 
Figure 11. Tg values of Carvedilol:Eudragit® L100-55 mixtures obtained from powder 
mixtures prepared directly in DSC pans. The error bar at 60% carvedilol is missing 
because only one Tg could be determined. .................................................................. 25 
Figure 12. Tg values of Indomethacin:Eudragit® L100-55 mixtures obtained from powder 
mixtures prepared directly in DSC pans. Three values are missing due to problematic 
determination of Tg values. .......................................................................................... 26 
Figure 13. HME strand of Carvedilol:HPMC-AS with 20% carvedilol content in the 
physical mixture. ......................................................................................................... 27 
Figure 14. Reversing heat flow from mDSC curves of two ASD replicates containing 20% 
(w/w) carvedilol measured at day 0. ............................................................................ 28 
Figure 15. WAXS and SAXS analysis, respectively, of ASD of carvedilol and HPMC-AS 
with 20% (w/w) carvedilol content. Blue and green colours represent results of two 
replicates. ..................................................................................................................... 28 
Figure 16. ATR-FTIR spectra in region typical for OH functional group stretching. Four 
spectra are compared: ASD with 20% (w/w) carvedilol (dark blue), amorphous 
carvedilol (red), crystalline carvedilol (black) and HPMC-AS (yellow). Spectra are 
displayed between 3,500 and 3,250 cm
-1
. .................................................................... 29 
Figure 17. ATR-FTIR spectrum of ASD with 20% (w/w) carvedilol (dark blue) compared 
to spectrum of amorphous carvedilol (red), crystalline carvedilol (black) and HPMC-
AS (yellow). The spectral region between 1,800 and 1,550 cm
-1
 is shown because it 
includes the region characteristics for carbonyl functional group stretching. ............. 30 
Figure 18. HME strand of Carvedilol:HPMC-AS with 40% (w/w) carvedilol content. .... 31 
Figure 19. Reversing heat flow from mDSC curves of two ASD replicates containing 40% 
(w/w) carvedilol measured at day 0. ............................................................................ 31 
 VI 
Figure 20. WAXS and SAXS analysis, respectively, of ASD of carvedilol and HPMC-AS 
with 40% (w/w) carvedilol content. Blue and green colours represent results of two 
replicates. ..................................................................................................................... 32 
Figure 21. ATR-FTIR spectra in region typical for OH functional group stretching. Four 
spectra are compared: ASD with 40% (w/w) carvedilol (dark blue), amorphous 
carvedilol (red), crystalline carvedilol (black) and HPMC-AS (yellow). Spectra are 
displayed between 3,450 and 3,280 cm
-1
. .................................................................... 33 
Figure 22. ATR-FTIR spectrum of ASD with 40% (w/w) carvedilol (dark blue) compared 
to spectrum of amorphous carvedilol (red), crystalline carvedilol (black) and HPMC-
AS (yellow). The spectral region between 1,800 and 1,540 cm
-1
 is provided because it 
includes the region characteristics for carbonyl functional group stretching. ............. 34 
Figure 23. HME strand of Indomethacin:HPMC-AS with 20% (w/w) indomethacin 
content. ........................................................................................................................ 34 
Figure 24. Reversing heat flow from mDSC curves of two ASD replicates containing 20% 
(w/w) indomethacin measured at day 0. ...................................................................... 35 
Figure 25. WAXS and SAXS analysis, respectively, of ASD of indomethacin and HPMC-
AS with 20% (w/w) indomethacin content. Blue and green colours represent results of 
two replicates. .............................................................................................................. 36 
Figure 26. ATR-FTIR spectrum of ASD with 20% (w/w) indomethacin (dark blue) 
compared to spectrum of amorphous indomethacin (red), crystalline indomethacin 
(black) and HPMC-AS (yellow). The spectral region between 1,800 and 1,550 cm
-1
 is 
provided because it includes the region characteristics for carbonyl functional group 
stretching. .................................................................................................................... 36 
Figure 27. HME strand of Indomethacin:HPMC-AS with 40% (w/w) indomethacin 
content. ........................................................................................................................ 38 
Figure 28. Films of indomethacin and HPMC-AS in a silicone mould. Drug loading in the 
powder mixture is increasing from left to right. The film in the red circle is due to 
40% (w/w) indomethacin in the mixture. Slightly transparent yellowish parts may 
represent phase separation of amorphous indomethacin from amorphous HPMC-AS, 
while the non-transparent yellowish part might contain crystals of indomethacin. .... 38 
Figure 29. Reversing heat flow from mDSC curves of two ASD replicates containing 40% 
(w/w) indomethacin measured at day 0. ...................................................................... 39 
 VII 
Figure 30. WAXS and SAXS analysis, respectively, of ASD of indomethacin and HPMC-
AS with 40% (w/w) indomethacin content. Blue and green colours represent results of 
two replicates. .............................................................................................................. 40 
Figure 31. ATR-FTIR spectrum of ASD with 40% (w/w) indomethacin (dark blue) 
compared to spectrum of amorphous indomethacin (red), crystalline indomethacin 
(black) and HPMC-AS (yellow). The spectral region between 1,800 and 1,500 cm
-1
 is 
shown because it includes the region characteristics for carbonyl functional group 
stretching. .................................................................................................................... 41 
Figure 32. Comparison of Tg values of ASD with 20% (w/w) carvedilol during stability 
study with two Tg values of ASD powder from a closed container at 1-week time 
point. The average Tg of samples from closed containers was calculated from Tg of 
mixtures and does not include single value of pure amorphous carvedilol at 1-week 
time point. .................................................................................................................... 42 
Figure 33. mDSC plot showing reversing heat flow from the mDSC curve with two Tg 
values: Tg1 at 42.3 °C and Tg2 at 96.4 °C (marked by arrows). An amorphous phase 
separation occurred for one of the two ASD replicates with 20% (w/w) carvedilol in 
the closed glass vial after one week’s storage in the stability chamber. ..................... 43 
Figure 34. An overview of all WAXS and SAXS measurements performed during the 
stability study of ASD containing 20% (w/w) carvedilol. Colours represent results of 
each time point during the stability study. ................................................................... 44 
Figure 35. ATR-FTIR spectra of ASD with 20% (w/w) carvedilol during stability study. 
The region of OH stretching is illustrated. .................................................................. 45 
Figure 36. ATR-FTIR spectra of ASD with 20% (w/w) carvedilol during the stability 
study. The upper part of C=O band is shown for better visualization. ........................ 46 
Figure 37.  Individual and average Tg values of all ASD samples with 40% (w/w) 
carvedilol at each time point during stability study. .................................................... 47 
Figure 38. An overview of all WAXS and SAXS measurements performed during the 
stability study of ASD containing 40% (w/w) carvedilol. Colours represent results of 
each time point during the stability study. ................................................................... 48 
Figure 39. ATR-FTIR spectra of ASD with 40% (w/w) carvedilol during the stability 
study. The region of OH stretching is illustrated. ....................................................... 49 
Figure 40. ATR-FTIR spectra of ASD with 40% (w/w) carvedilol during the stability 
study. The upper part of the C=O band is shown for better visualization. .................. 49 
 VIII 
Figure 41. Individual and average Tg values of all ASD samples with 20% (w/w) 
indomethacin at each time point during the stability study. ........................................ 50 
Figure 42. Overview of all WAXS and SAXS measurements performed during the 
stability study of ASD containing 20% (w/w) indomethacin. Colours represent results 
of each time point during the stability study. .............................................................. 51 
Figure 43. ATR-FTIR spectra of ASD with 20% (w/w) indomethacin during the stability 
study. The region of carbonyl stretching is illustrated. ............................................... 52 
Figure 44. Individual and average Tg values of all ASD samples with 40% (w/w) 
indomethacin at each time point during the stability study. The Tg value of the sample 
from an open container at the 1-month time point is missing due to difficulties 
estimating the glass transition. .................................................................................... 53 
Figure 45. DSC plot of ASD with 40% (w/w) indomethacin content measured after one 
week of storage in an open container in the stability chamber. Glass transition, 
crystallization exotherm and melting endotherm are observed for one of the two 
replicate samples. ........................................................................................................ 53 
Figure 46. Overview of all WAXS and SAXS measurements performed during the 
stability study of ASD containing 40% (w/w) indomethacin. Colours represent results 
of each time point during the stability study. .............................................................. 55 
Figure 47. ATR-FTIR spectra of ASD with 40% (w/w) indomethacin during the stability 
study. The region of carbonyl stretching is illustrated. ............................................... 55 
Figure 48. Non-reversing heat flow from mDSC curves of ASD containing 20% (w/w) 
indomethacin obtained after specific aging times are used for illustration purposes. 
The curves have been shifted for presentation reasons along both axes. .................... 59 
Figure 49. Recovered enthalpies as a function of time: ASD with 20% (w/w) carvedilol 
(●); ASD with 40% (w/w) carvedilol (▲); ASD with 20% (w/w) indomethacin (■); 
ASD with 40% (w/w) indomethacin (◆). ................................................................... 59 
Figure 50. Overview of relaxation functions as a function of time: ASD with 20% (w/w) 
carvedilol (●); ASD with 40% (w/w) carvedilol (▲); ASD with 20% (w/w) 
indomethacin (■); ASD with 40% (w/w) indomethacin (◆). ..................................... 60 
 
 
 
 IX 
LIST OF TABLES: 
 
Table I. Technical HME parameters for all powder mixtures. ........................................... 18 
Table II. Recovered enthalpies of ASDs aged at different annealing temperatures. .......... 60 
Table III. Structural relaxation times, stretched exponential parameters and the relaxation 
time constants of ASDs. .............................................................................................. 61 
  
 X 
ABSTRACT 
 
Amorphous solid dispersions provide one of the few approaches available for improving 
the solubility of poorly water-soluble active pharmaceutical ingredients. They are mainly 
2-component systems consisting of drug and polymer, where the amorphous drug is 
molecularly dispersed in an amorphous polymer matrix. The presence of polymer helps to 
maintain the drug in an amorphous state, which is thermodynamically unstable due to the 
possession of excess Gibbs free energy, enthalpy and entropy. To delay or prevent 
crystallization, the molecular mobility of the amorphous glass should be sufficiently low to 
avoid nuclei formation and crystal growth and is achieved by the maintaining the 
amorphous solid dispersion at a specific storage temperature and conditions, together with 
strong drug-polymer interactions. One of the major preparation processes for amorphous 
solid dispersions involves hot melt extrusion, producing solid dispersions at elevated 
temperatures without solvents. Four amorphous solid dispersions of 20% and 40% (w/w) 
carvedilol and indomethacin were manufactured using HPMC-AS as a polymeric carrier. 
Solid dispersions were characterized as freshly manufactured powders, as they were during 
a 1-month stability study using various analytical methods. Attention was paid to the 
molecular interactions in solid dispersions, miscibility, phase separation, crystallinity and 
molecular mobility. Solid dispersions of carvedilol exhibited satisfactory stability, which 
was reflected in preservation of amorphous carvedilol due to the sufficiently high glass 
transition temperature of the solid dispersions and the drug-polymer interactions. 
Indomethacin solid dispersions demonstrated the importance of drug loading in solid 
dispersions, together with the moderate or weak intermolecular interactions between drug 
and polymer. The enthalpy relaxation provides information regarding the lower molecular 
mobility of carvedilol in solid dispersions, indicating sufficient stabilization of amorphous 
drug by the selected polymer. Moreover, the intermolecular interactions were studied 
below and higher than the glass transition of the mixtures with different drug loadings, 
using temperature-dependent infrared spectroscopy. During this experiment, it was found 
that the intermolecular hydrogen bonds varied with the composition and measured 
temperature, resulting in disruption of intermolecular hydrogen bonds after passing the 
glass transition temperature. 
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POVZETEK 
 
Uporaba amorfnih trdnih disperzij je en izmed načinov izboljšanja hitrosti raztapljanja v 
vodi slabo topnih zdravilnih učinkovin. Amorfne trdne disperzije vsebujejo amorfno 
zdravilno učinkovino, ki je dispergirana v polimernem matriksu. Prisotnost polimera je 
potrebna zaradi stabilizacije amorfne oblike zdravilne učinkovine, ki je nagnjena h 
kristalizaciji, kar ogroža stabilnost končnega produkta. Razlog termodinamske 
nestabilnosti amorfne oblike je v njenih lastnostih: izkazuje višjo Gibbsovo prosto 
energijo, entropijo, entalpijo in prosti volumen. Amorfno obliko namreč največkrat 
pripravimo s hitro ohladitvijo kapljevine snovi, ki se je stalila pri temperaturi tališča. V 
primeru, da staljeno snov ohlajamo dovolj hitro, ne pride do kristalizacije, saj molekule 
niso imele dovolj časa, da bi se uredile in oblikovale kristale. Takšno tekoče agregatno 
stanje imenujemo podhlajena kapljevina. Z nadaljnjim zniževanjem temperature prihaja do 
strukturne prerazporeditve molekul kapljevine. Pri dovolj nizki temperaturi je gibanje 
molekul onemogočeno in celotna struktura nekako zamrzne. Ta dogodek se zgodi pri 
temperaturi steklastega prehoda, ki je lastnost amorfnih snovi. Gibanje molekul pod 
temperaturo steklastega prehoda je minimalno, nad njo je pa dovolj izrazito, da lahko pride 
do kristalizacije snovi. Veliko amorfnih zdravilnih učinkovin ima nizko vrednost 
temperature steklastega prehoda in iz tega razloga jo poskušamo zvišati z dodatkom 
polimera, ki s svojo višjo temperaturo steklastega prehoda deluje kot protimehčalo. 
Dodatno pa lahko polimer stabilizira amorfno zdravilno učinkovino preko tvorbe 
vodikovih vezi tako, da je gibanje molekul zdravilne učinkovine oteženo. Stabilnost 
amorfnih trdnih disperzij je torej velik in pomemben tehnološki izziv in je tudi možen 
razlog za majhno število tovrstnih produktov na tržišču.  
Namen naloge je bila izdelava in ovrednotenje amorfnih trdnih disperzij karvedilola in 
indometacina s polimeri HPMC-AS in Eudragit® L100-55, ter ovrednotenje njihove 
stabilnosti v času enomesečne stabilnostne študije. Z metodo iztiskanja talin smo izdelali 4 
amorfne trdne disperzije s polimerom HPMC-AS z 20% in 40% deležem zdravilne 
učinkovine. Amorfne trdne disperzije so bile v obliki praška. Delež zdravilne učinkovine v 
trdni disperziji smo izbrali na podlagi predhodno izdelanih filmov zdravilne učinkovine in 
polimera pri različnih deležih zdravilne učinkovine. Vsakemu filmu smo s pomočjo 
diferenčne dinamične kalorimetrije določili temperaturo steklastega prehoda, ki se je 
nahajala med temperaturama steklastega prehoda zdravilne učinkovine in polimera. Na 
 XIII 
podoben način smo želeli določiti vrednosti temperatur steklastega prehoda filmov s 
polimerom Eudragit® L100-55, vendar smo bili neuspešni. Vrednosti smo zatem poskusili 
določiti praškastim zmesem, ampak so bili rezultati nerazložljivi. Iz tega razloga smo se 
odločili, da polimer Eudragit® L100-55 opustimo v nadaljnjih raziskavah. Pri HPMC-AS 
amorfnih trdnih disperzijah smo ugotovili, da se eksperimentalno dobljene vrednosti 
razlikujejo od napovedanih izračunanih vrednosti, kar je potrjevalo, da so medmolekularne 
interakcije med karvedilolom in HPMC-AS močnejše kot med posameznimi molekulami 
zdravilne učinkovine. V primeru indometacina smo izmerili nekoliko znižane vrednosti 
temperatur steklastega prehoda, kot smo napovedovali, kar nakazuje na šibkejše 
medmolekularne interakcije med indometacinom in polimerom. Posledično zato obstaja 
večja verjetnost za tvorbo kristalizacijskih jeder, ker bodo molekule indometacina težile k 
združevanju in kristalizaciji oz. nestabilnosti.  
Za vrednotenje amorfnih trdnih disperzij smo poleg dinamične diferenčne kalorimetrije 
uporabili še infrardečo spektroskopijo s Fourierovo transformacijo, in sicer tehniko 
oslabljenega totalnega odboja in metodo malokotnega in širokokotnega rentgenskega 
sipanja. S pomočjo analiznih metod smo potrdili, da nam je uspelo izdelati amorfne trdne 
disperzije. Izjema je bila amorfna trdna disperzija s 40% vsebnostjo indometacina, kjer so 
bili poleg amorfne oblike prisotni tudi kristali zdravilne učinkovine. Rezultat je posledica 
presežene topnosti indometacina v polimeru, kar nakazuje, da je pri višjih odmerkih 
indometacina potrebno uporabiti več polimera, ali pa drugi polimer. Pri ostalih amorfnih 
trdnih disperzijah ni bilo tovrstnih težav in prisotnost amorfne zdravilne učinkovine je bila 
razvidna iz rezultatov meritev. Potrdili smo, da je uporabljen postopek primeren za 
izdelavo, z infrardečo spektroskopijo pa smo potrdili prisotnost vodikovih vezi med 
zdravilno učinkovino in polimerom.  
V enomesečni stabilnostni študiji nas je zanimalo ali so amorfne trdne disperzije sposobne 
ohraniti svoje lastnosti v primeru, če so shranjene pri temperaturi 40 °C in 75% relativni 
vlažnosti. Taki pogoji imajo lahko različen vpliv na posamezne amorfne trdne disperzije, 
saj ima vsaka amorfna trdna disperzija svojo vrednost temperature steklastega prehoda in 
shranjevanje amorfne trdne disperzije blizu te vrednosti lahko pospeši kristalizacijo. 
Prisotnost vlage ni zaželena, ker prav tako lahko zniža vrednost temperature steklastega 
prehoda (deluje kot mehčalo) in je zato ogrožena stabilnost amorfne zdravilne učinkovine. 
Za namene študije stabilnosti so bili vzorci shranjeni v odprtih in zaprtih steklenih 
vsebnikih. Ugotovili smo, da sta obe amorfni trdni disperziji s karvedilolom ohranili svoje 
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lastnosti v času celotne stabilnostne študije. Rezultati nakazujejo, da je bila zdravilna 
učinkovina prisotna v amorfni obliki ne glede na to, ali je bil vzorec shranjen v zaprtem ali 
odprtem vsebniku. Vrednosti temperatur steklastega prehoda amorfnih trdnih disperzij se 
niso bistveno spremenile. Tudi v tej študiji smo potrdili prisotnost intermolekularnih 
vodikovih vezi. Primerljivost rezultatov med vzorci v odprtih in zaprtih vsebnikih 
nakazuje, da je polimer HPMC-AS primeren za izdelavo stabilnih amorfnih trdnih 
disperzij z različnimi odmerki karvedilola. Tovrstni polimer je stabiliziral tudi amorfno 
trdno disperzijo s 40% vsebnostjo karvedilola, čeprav je njena temperatura steklastega 
prehoda nižja zaradi večje vsebnosti zdravilne učinkovine, kar bi lahko v pogojih študije, 
40 °C in 75% relativni vlažnosti močno pospešilo kristalizacijo. 
Amorfna trdna disperzija, ki je vsebovala 20% indometacina je ostala nespremenjena v 
času enomesečnega opazovanja. Nobena od uporabljenih analiznih metod ni zaznala 
prisotnost kristalov zdravilne učinkovine. Amorfna trdna disperzija z višjo vsebnostjo 
indometacina (40%) je že v začetku vsebovala kristale zdravilne učinkovine, ki smo jih 
detektirali z dinamično diferenčno kalorimetrijo, ne pa z metodo rentgenskega sipanja. 
Metoda rentgenskega sipanja je potrdila prisotnost kristalov v vzorcih v odprtih vsebnikih, 
in sicer že po dveh tednih. Predpostavljamo, da je temu vzrok nižja temperatura steklastega 
prehoda in predvsem vpliv vlage. V nadaljevanju nas je tudi zanimalo, kako se spekter 
infrardeče spektroskopije spreminja s temperaturo. Preko tega se da zaznati prisotnost 
vodikovih vezi med obema zdravilnima učinkovinama in HPMC-AS. Meritve smo izvedli 
pred in po temperaturah steklastega prehoda in potrdili smo, da je prišlo do prekinitve 
interakcij po prehodu temperatur steklastega prehoda pri vseh koncentracijah zdravilne 
učinkovine. Gre za potrditev pomembnosti upoštevanja temperature shranjevanja glede na 
temperaturo steklastega prehoda vzorca, saj je nad njo velika verjetnost za združevanje 
molekul zdravilne učinkovine zaradi večje gibljivosti molekul ter zaradi prekinitve 
medmolekularnih interakcij s polimerom. 
Znano je, da amorfne snovi izkazujejo višjo Gibbsovo prosto energijo, kar termodinamsko 
ni ugodno in jo zato želijo znižati, kar se manifestira z relaksacijo. Ta se začne takoj po 
izdelavi amorfne oblike, je pa lahko hitrost relaksacije različna. Zniževanje Gibbsove 
proste energije lahko doseže končno vrednost, ko amorfna oblika doseže vrednosti 
ravnotežne krivulje podhlajene tekočine. Relaksacijo v praksi lahko določamo z dinamično 
diferenčno kalorimetrijo, kjer določamo entalpijo vzorca. Vzorec v obdobju relaksacije 
entalpijo izgublja. Dinamika relaksacije napoveduje mobilnost molekul pod temperaturo 
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steklastega prehoda. Pri naši študiji smo določili daljše relaksacijske čase amorfnih trdnih 
disperzij s karvedilolom. Daljši povprečni relaksacijski časi nakazujejo, da se amorfna 
oblika bolj počasi relaksira, o čemer odločajo interakcije med zdravilno učinkovino in 
polimerom. 
Na podlagi dveh modelnih sistemov smo pokazali kateri dejavniki vplivajo na lastnosti in 
stabilnost amorfnih trdnih disperzij. Hkrati smo ugotovili, da vsaka zdravilna učinkovina 
potrebuje za stabilizacijo specifičen polimer. Zato ni univerzalnih rešitev stabilizacije 
amorfnih trdnih disperzij s polimernimi matriksi.  
 
Ključne besede: amorfne trdne disperzije, karvedilol, indometacin, metoda iztiskanja 
talin, stabilnost 
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1. INTRODUCTION  
 
1.1 Classification of amorphous solid dispersions 
 
Amorphous solid dispersions (ASDs) are one of the few approaches available for 
improving the solubility of poorly water-soluble active pharmaceutical ingredients (APIs). 
There are many compounds with high affinity and selectivity for their targets, but their 
aqueous solubility and therefore their oral bioavailability is insufficient. If the compound is 
intended to act as an API after oral application, it has to dissolve in the available volume of 
gastrointestinal fluids, permeate across the gut membrane, pass first metabolism and enter 
the systemic blood flow. Problems occur when the used dose of API cannot dissolve in 
gastrointestinal fluids and to overcome this pharmaceutical challenge, there are various 
solubilization methods available, including salt formation, cyclodextrin complexes, self-
emulsifying drug delivery systems, nanosuspensions, particle size reduction, use of 
surfactants and use of ASD as well.  
 The term solid dispersion was first defined as "a dispersion of drug in a solid 
matrix where the matrix was either a small molecule or polymer" (1). The dispersions 
could be divided into possible physical states:  
 eutectic mixtures  
 solid solutions and  
 glass solutions/suspensions (2).  
When two components are mixed at a specific ratio and their common melting point is 
lower than the melting point of individual components, a eutectic mixture is formed. If the 
specific ratio is preserved, components also crystallize at the eutectic temperature, 
otherwise one of the components will crystallize before the other (2). Solid solutions 
contain a distributed solute in a crystalline carrier and glass solutions/suspensions, which 
comprise solute molecules dispersed in the amorphous polymeric matrix or an amorphous 
phase which separates from the amorphous polymer phase in the glass suspension.  
Today, solid dispersions are defined as "dispersion of drug in an amorphous polymer 
matrix where the drug is preferably in the molecularly dispersed state", previously referred 
to as glass solutions (1). Solid dispersions are therefore mainly 2-component systems 
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consisting of an API and polymer, although additives such as a surfactant could also be 
used. ASD will during contact with aqueous media dissolve due to the hydrophilic 
polymeric carrier, with the API being subsequently released to form a supersaturated 
solution (3). When this solution is formed, it tends to precipitate out, a process which is 
undesirable because ASDs are manufactured with the aim of improving oral bioavailability 
of poorly water-soluble drugs. To maintain an API in its supersaturated conditions, it has 
to be stabilized via drug-polymer interactions. ASD may be formulated with as high as 
possible drug loading and no amorphous-amorphous phase separation or crystallization 
occurs during product shelf-life (4).   
The amorphous form is usually prepared from a crystalline solid by rapid cooling of the 
melted compound, rapid precipitation from solution or by milling (5). When the melted 
compound is cooled, the crystalline solid is firstly heated and then melts at the melting 
temperature (Tm). Figure 1 illustrates the temperature dependence of thermodynamic 
properties:  
 
 
Figure 1. Plot of thermodynamic properties against temperature. Modified from (6). 
 
Melting of the solid occurs at the Tm with the break at Tm. During melting, the crystal 
lattice breaks down because the heat provides the molecules with sufficient energy to 
overcome the attractive forces that hold the crystal together (7). The heat absorbed by the 
solid is termed latent heat of melting; the temperature of the solid will not increase until 
the entire sample melts and becomes liquid. If the liquid were cooled, it would crystallize 
back at Tm and the system then has a lower specific volume, enthalpy and entropy. This 
process occurs when the cooling is sufficiently slow and molecules have enough time to 
move from their current location to their energetically preferred point, upon which crystal 
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formation begins (8). If the liquid is cooled relatively quickly, the molecules cannot 
rearrange significantly, and crystallization is inhibited. This state is referred to as a super-
cooled liquid. The specific volume and enthalpy of a liquid follow the equilibrium line of 
the liquid below Tm because the low viscosity and high molecular mobility help to follow 
the decrease of the temperature (6). Further cooling causes a reduction in molecular motion 
and due to the increasing material viscosity, molecules move slowly and have insufficient 
time to rearrange themselves as the temperature decreases. At some point, molecular 
mobility is so slow that the system freezes and enters a glassy state at the glass transition 
temperature (Tg).  
Thus, Tg represents the change in molecular mobility, with molecules exhibiting 
vibrational motion in a disordered glass, but not translational or rotational. Tg is a property 
of amorphous material; when such material is stored at temperatures below Tg, it is hard 
and brittle (it is in the glassy state), while the material becomes rubbery above Tg (it is in 
the rubbery state). A glass is a system with the mechanical properties of the solid, with its 
disordered structure being similar to a liquid. The molecular motions are faster above Tg, 
allowing the material to crystallize. The cooling rate influences the value of Tg (although 
the dependence is relatively weak) and so amorphous states with slightly different energy 
levels are formed: a slower cooling rate leads to a lower Tg because this lower rate allows 
the material to stay in equilibrium until lower temperatures, while rapid cooling leads to a 
higher Tg (9).  
 
1.2 Stability of amorphous solid dispersions 
1.2.1 Role of polymer in amorphous solid dispersions 
 
The amorphous state exhibits a disorder structure because it lacks the repeating long-range 
arrangement of molecules and possesses higher Gibbs free energy; it therefore has a higher 
apparent water solubility and dissolution rate compared to crystalline materials. The excess 
Gibbs free energy and enhanced molecular mobility of amorphous materials are 
responsible for their higher chemical reactivity and instability because they tend to relax to 
the most stable form through recrystallization. To delay or prevent recrystallization, a 
polymer is added to the API to produce a solid dispersion with the purpose of preserving 
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its characteristics through a medicine’s shelf-life period. Depending on the carrier, either 
fast or controlled release systems may be produced (10). 
For the stability of amorphous form, the miscibility between a drug and polymer is 
important. Thus, they should be mixed at the molecular level to form a glass solution and 
the miscibility should also remain during storage conditions (2). Kinetic stabilization is 
achieved by immobilization of amorphous API in a viscous polymer matrix. Moreover, 
polymers act as an antiplasticizer and increase the Tg of amorphous API, thus kinetically 
inhibiting crystallization by lowering drug molecule mobility. When an ASD is formed, its 
Tg will lie in the range of pure amorphous compound Tg values; the Tg also provides 
information regarding drug-polymer interactions. Whether the forces between drug and 
polymer are adhesive or cohesive can be compared by calculating the Tg value of the 
mixture using the Gordon-Taylor equation (2): 
 
Tgmix = (w1Tg1 + Kw2Tg2) / (w1 + Kw2) 
 
in which w1 and w2 are weight fractions of the API and polymer in the mixture; Tg1 and Tg2 
are glass transition temperatures of pure amorphous compounds; and K is a constant 
calculated from Tg values of both compounds and their densities: 
 
K  1Tg1 / 2Tg2 . 
 
Deviations from the Gordon-Taylor equation in manufactured ASD provide information 
about adhesive or cohesive forces and therefore drug-polymer interactions. Among the 
intermolecular interactions, hydrogen bonds are the most important.      
Generally, the "Tg - 50" rule is used to provide an estimate of stability of amorphous form, 
considering that at 50 °C below Tg, molecular motions are minimal and therefore phase 
separation or crystallization are avoided (5). Although polymer can be added to improve 
physical stability of an amorphous API, it is still unstable and hence amorphous-
amorphous phase separation or crystallization can occur, even at temperatures below Tg 
(11).  
Instability of ASDs can further be accelerate by the presence of moisture because water 
acts as a good plasticizer and lowers the ASD Tg. Most amorphous materials absorb large 
quantities of water because disordered amorphous structures enable water molecules to 
 5 
pass into the bulk of an amorphous material (7). Furthermore, extensive or weak hydrogen 
bonding between drug and polymer leaves fewer sites available for bonding with moisture. 
However, hydrogen bonds may also be weakened by moisture, with the system 
subsequently becoming immiscible (12). In such an immiscible system, API molecular 
mobility is increased, leading to amorphous-amorphous phase separation with drug-rich 
and polymer-rich domains.   
Polymers used in ASDs should be inert, GRAS (generally recognized as safe), water 
soluble,  
thermally stable when a melting preparation method is used and soluble in organic solvents 
in the case of solvent methods, should possess high Tg and hydrogen donor and acceptor 
groups (13). The polymers most frequently used in ASD medicines are 
polyvinylpyrrolidone (PVP), polyvinylpyrrolidone/vinyl acetate (PVP/VA), 
polyvinylpyrrolidone/polyamide (PVP/PA), hydroxypropyl methylcellulose acetate 
succinate (HPMC-AS), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose 
(HPMC) and polyethylene glycol (PEG) (10). 
 
1.2.2 Recrystallization from amorphous state  
 
An amorphous state is thermodynamically unstable relative to the crystalline state and is 
prone to recrystallization. As mentioned previously, molecular mobility plays the key role 
in such a process, together with the Gibbs free energy difference between both states. 
Viscosity of the glass is the kinetic barrier for crystallization, together with strong drug-
polymer hydrogen bonds. The crystallization process begins with formation of nuclei, 
followed by crystal growth. An API can precipitate in an ASD in clusters, which grow and 
decay with time until stable nuclei are created (14). Thus, nuclei are formed when a certain 
degree of supersaturation is reached, providing sufficient energy to cross the nucleation 
barrier. In addition, the opportunity for nuclei formation is significantly increased when 
drug molecules are in the correct orientation and when drug-polymer hydrogen bonds are 
weakened or broken. Once the nuclei are present, they start to grow, and recrystallization 
initiates.  
Diffusion of API molecules towards the crystal interface, followed by integration of the 
molecules into the crystal lattice are required for crystal growth, a process connected to 
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molecular mobility. For this purpose, storage temperature is important because at 
temperatures close to or above Tg, molecular motions are sufficiently high.  
 
1.3 Relaxation 
 
Glass is in a non-equilibrium state and possesses excess Gibbs free energy, enthalpy and 
entropy. From the time that an ASD is manufactured, it loses excess enthalpy, entropy and 
volume (densification) towards a lower energetic state — the equilibrium line of a super-
cooled liquid. During this process, referred to as relaxation or physical aging, the API 
remains in amorphous form.  
The molecular mobility is connected with the relaxation time constant , which is longer 
below Tg because the glass exhibits high viscosity and molecular motions are restricted. 
The molecular motions take some time and there are most likely numerous relaxation 
processes within an ASD with a distribution of relaxation times; hence, the average of 
these times is represented by  (15). Relaxation time is connected with the process 
termed relaxation/mobility, representing molecular motions on a large length scale. This 
mobility is cooperative because more cooperation is required between the molecules to 
change their positions and the activation energy for the cooperation decreases with an 
increase in temperature near Tg (16). On the other hand, relaxation/mobility is non-
cooperative and is related to one part of a molecule, similar to the rotation of a side chain. 
These motions are faster, with a short  and small activation energy. When the temperature 
approaches Tg, relaxation times of both mobilities become increasingly shorter, and 
therefore their distribution narrower. Both relaxations merge and become identical at a 
particular temperature above Tg (16). 
The relaxation time can be expressed using several equations, such as the Kohlrausch-
Williams-Watts (KWW) equation (17). The calculations are based on measuring the 
enthalpy lost during annealing because an ASD loses its excess thermodynamically 
properties related to enthalpy, entropy and volume. Enthalpy loss can be detected by 
differential scanning calorimetry (DSC) because more heat has to be added to the sample 
to pass the Tg compared to a freshly manufactured ASD (Fig. 2).   
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Figure 2. Enthalpy-temperature diagram illustrating the enthalpy relaxation of an 
amorphous system (a), reheating the system (b) and enthalpy recovery (c). Ta is the 
annealing temperature. Modified from (18). 
H is the maximum enthalpy (energy available for relaxation) a sample can lose, and is 
related to enthalpic relaxation at a specific annealing time, Hrelax, by equation: 
 = 1 - Hrelax  /H 
where  is the relaxation function. It can take values from 0 (relaxation is complete) to 1 
(no relaxation).  
H can be obtained from the change in heat capacity, Cp, at Tg and temperatue, T, at 
which is glass annealed: 
H = Cp (Tg  - T). 
The relaxation function, , is fitted using non-linear regression to the KWW equation: 
 = exp [ - (t/)

],   
in which t is the time of annealing,  is the relaxation time and  the stretched exponential 
parameter.  values are between 0 and 1 and provide information about the distribution of 
molecular relaxation time, with 0 indicating a heterogeneous relaxation time and 1 a single 
relaxation time.   
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The KWW equation is not ideal because the experiments are performed at temperatures 
closer to Tg and not at actual storage temperature (13) — analysis time at actual storage 
temperatures may be too lengthy to detect the relaxation process with a large enthalpic 
recovery signal. Hence, results from the experiments are extrapolated to actual storage 
temperature far below Tg.  
 
1.4 Characterization of amorphous solid dispersions 
 
ASD, as a system, are part of the final dosage form and similarly also have to be 
characterized. Thus, the attributes of the amorphous system should be known in order to 
ensure its stability during shelf-life. Many analytical methods are available for 
characterizing ASD (19), although only a few are mentioned and employed in this work. 
Attention was paid to characteristics important for the stability of ASD: molecular 
interactions in ASD, miscibility, phase separation, crystallinity and molecular mobility.    
 
Differential scanning calorimetry 
This calorimetric technique is based on the measurements of the difference in heat flow 
into the sample and reference pan, which is usually an empty pan. Samples are placed in 
the furnace with a controlled flow of inert gas. During the controlled temperature 
programme, both pans can be heated, cooled or isothermal conditions may be held. 
DSC enables the observation of various endothermic and exothermic events. When 
samples are heated, the temperature of the sample pan may differ from the temperature of 
the reference pan, what causes the change in the heat flow. Endothermic events such as 
melting, glass transition, desolvation or enthalpy recovery absorb heat, and hence the 
sample pan has to be supplied by additional heat to reach the temperature of the reference 
pan. On the other hand, exothermic events such as crystallization or thermal decomposition 
liberate heat, leading to a reduction in heat flow into the sample pan.  
A DSC plot shows thermal events as heat flow versus temperature or time, in which Tg can 
be detected as a step in the change of heat capacity, Cp, during heating. After Tg, the 
sample temperature rises, but at a different rate compared to below Tg. Thermal events can 
occasionally overlap each other and small transitions cannot be detected, thus temperature-
modulated DSC can be used (mDSC). The total heat flow (THF) in mDSC is divided into 
two simultaneous heating rates — linear and modulated heating with a sinusoidal 
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temperature change (20). For periodic changes in heating rate, modulation period and 
modulation temperature amplitude have to be determined. Thus, mDSC measures THF 
consisting from reversing heat flow (RHF) represented by capacity component, and non-
reversing heat flow (NRHF), which is subtracted from THF by RHF. mDSC enables 
separation of events based on the change of heat capacity, such as Tg, from kinetic events 
like enthalpic recovery, evaporation or cold crystallization (19). mDSC can be used for the 
study of molecular interactions in ASD, miscibility, phase separation, crystallinity and 
molecular mobility.  
 
Attenuated total reflectance Fourier transformed infrared spectroscopy 
Attenuated total reflectance Fourier transformed infrared spectroscopy (ATR-FTIR) is a 
spectroscopic method based on infrared radiation, which interacts with the sample. Three 
regions of the IR spectrum are delineated according to radiation wavelength: far-IR, mid-
IR and near-IR. In this work, the mid-IR region between 4000 and 600 cm
-1
 was used for 
determination of functional groups of molecules — different functional groups absorb a 
specific IR radiation frequency, causing them to stretch or bend.  
Attenuated total reflection is popular sample technique, enabling measurement of solids 
and liquids without preparation. The method is based on the changes which occur in a 
reflected IR beam when it comes into contact with the sample (21). First, the IR beam is 
directed into the crystal, where it refracts, and an evanescent wave occurs. While the 
sample is in contact with the crystal, part of the wave is absorbed by the sample and the 
evanescent beam is attenuated and recorded by the detector. In the case of Fourier 
transform infrared spectroscopy (FTIR), an optical system consists of a beam splitter, 
movable mirror and stationary mirror. The IR beam is split into two beams: one is directed 
towards the movable mirror, another towards the stationary mirror. The beams are 
reflected back, meet at the beam splitter, recombine and interfere. According to the 
position of the movable mirror, the interference changes influence the detector signal. This 
beam then travels against the sample, ending at the detector. All signals are then converted 
by Fourier transformation into an IR spectrum.  
We used the spectrometer alone and also in the combination with the temperature-
controlled microscope stage to obtain sample spectra during the temperature change 
(temperature-dependent ATR-FTIR, TD ATR-FTIR).  
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ATR-FTIR is used for determination of molecular interactions within ASD by observing 
the regions typical for hydrogen bond vibrations.  
 
Small- and wide-angle X-ray scattering  
The technique measures the intensity of X-rays scattered by a sample as a function of the 
scattering angle (22). The sample is illuminated by a narrow, highly intense X-ray beam, 
which is scattered at different angles and elastic scattered radiation is then detected. The 
angle of the scattered beams varies according to the observed sample length scale. Small-
angle X-ray scattering (SAXS) is used for beams scattered 0,1-10° from the sample and 
provides information at the scale of 1–100 nm, while wide-angle X-ray scattering (WAXS) 
measures the scattering intensity at angles >10°, capturing structural information at < 1 
mm (19). A diffractogram of crystalline material is typical for compounds showing peaks 
at specific positions, with a certain intensity and peak width. An amorphous material's 
diffractogram lacks peaks, and weak scattering is observed as a broad continuous halo 
which is unique for every material. Measurements are typically provided in a vacuum to 
avoid any other scattering of the beam, except that related to the sample.    
SWAXS is used for determination of material's amorphicity/crystallinity.    
 
1.5 Manufacturing of amorphous solid dispersions 
 
There are two major preparation processes used by pharmaceutical companies to produce 
ASDs — melting and solvent evaporation.  
Spray drying is a solvent evaporation method based on the dissolution of an API and 
polymer in a common solvent, which is then removed, with the solution being converted 
into a dry powder (23). Evaporation proceeds at lower temperatures, and therefore the 
process is suitable for heat-labile APIs, although residual solvents may be problematic 
(24).  
Melting processes such as hot melt extrusion (HME) solubilize APIs in a melted 
amorphous polymer, followed by solidification of the extrudate. The extruder consists of 
one or two screws placed in temperature-controlled barrels (the temperature can be 
different in each barrel). The powder mixture of the API and polymer enters the barrels on 
one side and leaves them on the other side as a hot melt. The screws inside the barrels are 
constantly rotating, enabling mixing, dispersing, homogenizing, dissolving, conveying and 
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degassing of the mixture (25). The temperature inside the barrels should be above the 
polymer Tg, but not necessarily above the Tm of the API because mechanical energy inside 
the extruder generates heat (26). The hot extrudate then cools and solidifies at room 
temperature after it leaves the extruder. The extrudate strands may be milled or pellets may 
be formed. HME does not require any use of solvents and it is not suitable for processing 
of thermally labile APIs.  
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2. AIM 
 
The aim of this work is to manufacture and characterize carvedilol and indomethacin 
ASDs with HPMC-AS and Eudragit® L100-55 using HME. Carvedilol and indomethacin 
have a similar Tg, but their interactions with the polymer may differ. These interactions 
will be investigated within ASDs using various analytical methods such as DSC, ATR-
FTIR and SWAXS. The ASDs will be evaluated after manufacturing, as well as during a 1-
month stability study. Moreover, enthalpy relaxation will be analysed to provide a better 
understanding of the molecular mobility of drugs. Finally, hydrogen bond drug-polymer 
interactions will be investigated using TD ATR-FTIR. 
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3. MATERIALS AND METHODS 
 
To understand the characteristics of ASDs, two model systems were investigated by using 
two APIs — carvedilol and indomethacin — and two polymers — HPMC-AS and 
Eudragit® L100-55.   
Carvedilol (1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol) 
is a non-selective beta blocker used to treat mild to moderate congestive heart failure (27). 
Carvedilol's LogP is 4.19, with a melting point of 114.5 °C (27).  
 
Figure 3. Structure of carvedilol. Adapted from (28). 
 
 
Indomethacin (2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid) 
belongs to a group of non-steroidal anti-inflammatory drugs (NSAID), which has 
analgesic, anti-inflammatory and antipyretic properties (27). Indomethacin's LogP is 4.27, 
with a melting point of 151.0 °C (27). 
 
 Figure 4. Structure of indomethacin. Adapted from (28). 
  
 
 
Hydroxypropyl methylcellulose acetate succinate (HPMCS-AS) is a mixture of acetic 
acid and monosuccinic acid esters of hydroxypropyl methylcellolose, available in several 
grades and varying in terms of the substitution of acetyl and succinoyl groups (29). 
Substitution grade L has a higher acetyl and lower succinoyl content, while grade H is 
recognized for its highest acetyl and least succinoyl content (often expressed in 
percentages by weight) (29). Grade M lies between the two grades. All of these 
compounds are insoluble in acidic gastric fluid, but swell and dissolve in the upper small 
intestine, making them suitable for enteric coating. HPMC-AS has also been widely used 
in ASD formulations.  
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Figure 5. Structure of HPMC-AS. Adapted from 
(30). 
 
 
 
 
 
Eudragit® L100-55 is part of the Eudragit® polymer family, which comprise copolymers 
derived from esters of acrylic and methacrylic acid with various functional groups (31). 
This particular anionic polymer is used for enteric coating because it dissolves at a pH 
above 5.5 (31).  
 
Figure 6. Structure of Eudragit® L100-55. Modified from (32). 
 
 
 
 
n 
 
MATERIALS: 
Chemicals: 
 Carvedilol (Indoco Remedies, Ltd.) 
 Indomethacin (TCI, Tokyo Chemical Industry CO., Ltd.) 
 Hydroxypropyl methylcellulose acetate succinate (HPMC-AS LG) (Shin-Etsu 
Chemical) 
 Eudragit® L100-55 (Evonik Industries) 
 Acetone: HPLC grade (Carl Roth) 
 Methanol: HPLC grade (Carl Roth) 
 
ATR-FTIR/TD ATR-FTIR: 
 FTIR Spectrometer (Vertex 70, Bruker) 
 15 
 Temperature Controlled Microscope Stage (THMS600, Linkam Scientific 
Instruments) 
 Automatic Pipette: 0.5–10 l (Eppendorf Research Plus) 
 Pipette tips: 50–1,000 l (Eppendorf) 
 Analytical Balance (Excellence Plus XP205, Mettler Toledo)  
 Glass Snap Cap Vials (52x24 mm, 15 ml, Kimble) 
 Volumetric Pipette: 5 ml, 10 ml (Hirschmann) 
 Single-use Syringes: 5 ml (6 ml) (Norm-Ject Henke-Sass Wolf) 
 Syringe Filters: 0.22 m (Yeti) 
 
mDSC: 
 Differential Scanning Calorimeter (DSC 204 F1 Phoenix, Netzsch) 
 Analytical Balance (Excellence Plus XP205, Mettler Toledo)  
 Aluminum pans and lids for DSC (Netzsch) 
 
Gas pycnometry: 
 Gas Displacement Pycnometry System (AccuPyc II 1340, Micromeritics) 
 Analytical Balance (AW-224, Sartorius)  
 
Solution casted films: 
 Analytical Balance (SI-234A, Denver Instrument) 
 Glass Snap Cap Vials (52x24 mm, 15 ml, Kimble) 
 Volumetric Pipette: 5 ml (Hirschmann)  
 Single-use Syringes: 5 ml (6 ml) (Norm-Ject Henke-Sass Wolf) 
 Syringe Filters: 0.22 m (Yeti) 
 Ultrasonic Cleaner (Elmasonic S 10 H, Elma) 
 Silicone mould 
 Vacuum drying oven (VDx 53, Binder) 
 Chemistry pumping unit (PC 500 series, Vacuubrand) 
 
UV-VIS: 
 UV-VIS spectrophotometer (UV-2700, Shimadzu) 
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 UV cell: 10 mm (Hellma Analytics) 
 Volumetric flask: 50 ml (VWR) 
 Automatic Pipette: 100–1,000 l (Eppendorf Research Plus) 
 Pipette tips: 50–1,000 l (Eppendorf) 
 
HME: 
 Hot-melt extruder (ZE 9, Three-Tec) 
 Analytical Balance (SI-234, Denver Instrument) 
 3D shaker mixer (Turbula T 2 F, Willy A. Bachofen AG) 
 Cryogenic grinder (6875 Freezer/Mill, SPEX SamplePrep) 
 Vibratory sieve shaker (AS 200, Retsch)  
 
 SWAXS: 
 Small- and wide-angle X-ray scattering station (S3-MICRO, Hecus X-ray systems 
GmbH Graz) 
 
 
METHODS: 
1) Methods for obtaining Tg values of drug-polymer mixtures: 
 
Film casting with HPMC-AS 
Seven solutions of carvedilol with HPMC-AS and seven solutions of indomethacin with 
HPMC-AS were prepared with various drug loadings in the powder mixture: 10%, 20%, 
30%, 40%, 50%, 60% and 80% (w/w). Five ml of acetone was added to 250 mg of 
the powder blends to achieve a concentration of 5% (w/v). All samples were placed into an 
ultrasonic bath for ten minutes. Vortex stirred solutions were then filtered, poured into a 
silicone mould and transferred into a vacuum oven for one hour at 40 °C and a pressure of 
100 mbar. After evaporation of acetone, drug-polymer films were collected and stored in 
closed plastic bags in a desiccator.  
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Film casting with Eudragit® L100-55 
Fourteen solutions in total were made with Eudragit® L100-55 with the same drug 
loadings as with HPMC-AS. Ethanolic solutions with a concentration of 1% (w/v) were 
placed into an ultrasonic bath at 50 °C for ten minutes, poured into silicone mould and 
placed into a vacuum oven for 2.5 hours at 60 °C and a pressure of 100 mbar to allow the 
ethanol to evaporate. 
 
mDSC 
Two DSC samples from each casted film were prepared and measured using the mDSC 
method with modulated second heating. Films (5–8 mg) were prepared in 25 µl aluminum 
pans with a pierced lid to allow removal of the solvent. The samples were heated from 
room temperature to 180 °C at a heating rate of 10 °C/min and then cooled at the same rate 
to 0 °C. Second modulated heating started from 0 °C with a heating rate of 5 °C/min, 
amplitude ± 0.731 °C and a period of 40 s up to 180 °C.  
Experimental Tg values were compared to calculated values using the Gordon-Taylor 
equation. For calculations, Tg values of pure powder components were measured as two 
replicates performing the same mDSC programme, while densities of pure amorphous 
polymers were obtained by gas pycnometry. Densities of amorphous carvedilol and 
indomethacin were calculated considering the rule that the crystalline form has 10–20% 
higher density than amorphous forms (for calculations, the value of 15% was used) (33).  
The temperature programme for ASD was divided into two parts: 1) the sample was cooled 
from room temperature to 0 °C and then 2) heated using the same settings up to 180 °C.  
 
2) Method of manufacturing ASD: 
 
HME 
HME was produced using a tabletop version of a hot-melt extruder for the smallest 
quantities of material. Two powder mixtures with 20% and 40% (w/w) of both APIs 
(together four powder mixtures) were chosen for HME. Granular HPMC-AS was 
previously milled and mixed with APIs at 40 Hz for 15 minutes to obtain a homogeneous 
mixture. Thirty-eight grams of powder mixtures were prepared and extruded. The 
following extrusion parameters were used (Table I): 
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Table I. Technical HME parameters for all powder mixtures. 
Sample 
Barrel 1 
temperature 
[°C] 
Barrel 2 
temperature 
[°C] 
Barrel 3 
temperature 
[°C] 
Motor 
speed 
[rpm] 
20% (w/w) Car:HPMC-AS 120 150 150 120 
40% (w/w) Car:HPMC-AS 110 140 140 120 
20% (w/w) Ind:HPMC-AS 120 150 150 120 
40% (w/w) Ind:HPMC-AS 110 140 140 120 
 
Following HME, strands were broken into small pieces and milled in a nitrogen 
atmosphere for two minutes with 15 cycles per second and eight minutes precooling prior 
to grinding. HME strands containing 40% (w/w) carvedilol and indomethacin were milled 
for three minutes because there was a large fraction of unmilled material observed during 
sieving of carvedilol strands with 20% (w/w). As mentioned previously, all ASD were 
gradually sieved using a vibratory sieve shaker through a 200m sieve with a vibration 
height of 1 mm for five minutes. The samples and powder residues were stored in closed 
containers sealed with parafilm in a refrigerator for the next day, when the characteristics 
of ASDs were investigated using mDSC, SWAXS, ATR-FTIR methods and UV-VIS. 
Because part of our interest was also a stability study of ASD samples, this day was 
considered to be day 0. Next, analyses were performed after one week, two weeks and one 
month. For this purpose, approximately 1.5 g of the sample was stored in each glass vial at 
40 °C and 75% RH in a stability chamber. There were eight glass vials stored: four with 
open lids and four closed and sealed with parafilm (eight vials of each ASD including the 
time point of three months, data which do not form part of this thesis). Drug concentration 
in the sample was measured with a UV-VIS spectrophotometer for three replicates at day 
0. The remaining analytical techniques were used at every time point, with samples being 
measured in two replicates.  
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3) Method for investigation of hydrogen bonds between APIs and HPMC-AS:  
 
ATR-FTIR 
ASD powders were placed on the IR crystal and samples were measured as two replicates 
in the range 4000–600 cm-1 with a spectral resolution of 4 cm-1. Sixty scans were obtained 
from each measurement.  
 
TD ATR-FTIR 
Drug-polymer molecular interactions were investigated by using a combination of ATR-
FTIR and a temperature-controlled stage. The hydrogen bond interactions and their 
potential changes were observed with increasing temperature. During heating, every 
sample was measured ten times at various temperatures to gain spectra before and after Tg, 
as well as at Tg. Samples were heated with a heating rate of 5 °C/min up to 130 °C, which 
is the maximum allowed temperature applied to FTIR crystal. Measurements were 
performed at certain temperatures, with an isothermal hold time of two minutes. FTIR 
spectra measured in the range 4000–600 cm-1 with a spectral resolution of 4 cm-1 and 60 
scans for each sample were obtained. 
Samples were prepared as acetonic solutions of APIs and polymer at a concentration of 5 
mg/ml with different drug loadings. All solutions were filtered through a 0.22 m syringe 
filter and 10 L of the filtered solution was placed on the FTIR crystal. To obtain a film of 
API and polymer, several seconds were allowed to pass to let the acetone evaporate, with 
the temperature-controlled stage then being placed on an in situ casted film.  
 
4) Method for evaluation of amorphicity/crystallinity of ASD: 
 
SWAXS 
The possible presence of API crystals in ASD was investigated using the SWAXS method. 
SWAXS patterns were collected simultaneously using a system with a beam of Cu-Kα 
radiation at a wavelength of 1.542 Å produced by a point-focusing camera system (Hecus-
S3-MICROSWAXS, Bruker AXS). X-ray beams were sent through the specimen, with 
scattered patterns then being collected using two detectors to cover the resolution ranges of 
> 10º for WAXS and 0.1–10º for SAXS. Samples were measured in a glass capillary 
sealed with a flame, with the capillary then being placed into a capillary rotation unit. 
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Samples were measured in two replicates at room temperature and with an exposure time 
of 5 minutes in a vacuum.  
 
5) Method for evaluation of ASD structural relaxation:  
 
Structural relaxation was investigated at a specific annealing temperature (Ta) chosen for 
each ASD individually within the DSC temperature programme. Approximately 5 mg of 
the sample was weighed into a 25 µl aluminium pan with a pierced lid. The samples were 
heated from room temperature to 20 °C above their Tg at a heating rate of 10 °C/min and 
then cooled at the same heating rate to room temperature, followed by further heating to 
the Ta. The Ta was selected approximately 20 °C below the sample's Tg:  
 
 70 °C for ASD with 20% (w/w) carvedilol content; 
 50 °C for ASD with 40% (w/w) carvedilol content; 
 60 °C for ASD with 20% (w/w) indomethacin content; 
 25 °C for ASD with 40% (w/w) indomethacin content. 
 
Ta was held isothermally for 1, 2, 4, 8 and 12 hours. Samples were subsequently cooled to 
room temperature and heated to 20 °C above their Tg with a modulated temperature 
programme consisting of a heating rate of 10 °C/min, amplitude ± 0.731 °C and a period of 
40 s. Samples of ASD with 40% (w/w) indomethacin content were cooled to 0 °C during 
the temperature programme due to the low Ta. All measurements were performed in two 
replicates. Enthalpy relaxation data were calculated using Microsoft Excel Solver.  
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4. RESULTS AND DISCUSSION 
 
The preparation of ASDs has several advantages, such as improving the solubility of 
poorly water-soluble APIs, enhancing their dissolution, the possibility of using high drug 
loadings and robust manufacturing processes. In spite of these advantages, the stability of 
ASD is the main concern of pharmaceutical formulation scientists and besides ASD 
formulation, attention should also be paid to storage conditions because ASD needs to be 
kinetically stable at specific storage temperatures during the shelf life of a medicine.  
Before the ASDs were produced, the drug-polymer mixtures were characterized. First, the 
casted films and powder mixtures were prepared to evaluate the Tg values of different drug 
concentrations in the mixtures. Casted films of amorphous APIs and polymers were 
prepared using the solvent casting method and their Tg values, as well as Tg values of 
powder mixtures, were determined using mDSC. From all the mixtures, four different 
drug-polymer compositions in total were chosen and four ASDs were manufactured by 
HME. The second part of the work focuses on the physical stability of ASDs.  
 
4.1 Determination of Tg values 
 
Determination of Tg values of Carvedilol:HPMC-AS casted films 
For physical stability, it is essential to determine the Tg of ASDs because after passing the 
Tg, the mobility of molecules is sufficient for nucleation and crystal growth. When the 
mixture of polymer and API is prepared, in most cases, it has a Tg between the two Tg 
values of both compounds. The experimental data show continuously decreasing Tg with 
increasing drug content in the physical mixture (Fig. 7).  
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Figure 7. Tg values of Carvedilol:HPMC-AS mixtures showing decreasing Tg values with 
increasing mixture drug content. Tg value have been obtained by mDSC. 
 
These data confirm that the API acts as plasticizer for the polymer (and the polymer acts as 
an antiplasticizer for the API); thus, the Tg of the mixture decreases when more API is 
added to the powder mixture. In comparison to theoretical Tg values, there is a positive 
deviation present because all experimental Tg values are higher than the theoretical ones 
(Fig. 8).  
 
 
Figure 8. Comparison of Carvedilol:HPMC-AS Tg values obtained from film-casted 
method (blue line) and calculated theoretical values (orange line). 
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This result indicates that drug-polymer interactions are more favourable than drug-drug or 
polymer-polymer interactions. Intermolecular interactions between the API and polymeric 
matrix result in formation of hydrogen bonds because both molecules have hydrogen donor 
and hydrogen acceptor groups. Such a system is more likely to be stable due to the fact that 
the tendency of amorphous API to crystallize is decreased at specific storage temperatures. 
Furthermore, hydrogen bonds between drug and polymer help to maintain the 
supersaturated drug concentration during dissolution after the application. The 
antiplasticizing effect of the polymer elevates the Tg of the API, a process which also 
lessens its crystallization tendency because the polymer increases viscosity along with 
reducing the molecular mobility of the API, with the formation of stable nuclei 
subsequently being restricted. Antiplasticization is lowered from 50% of drug content in 
the powder mixture; thus, drug loading should be considered during medicine formulation.   
 
Determination of Tg values of Indomethacin:HPMC-AS casted films 
The results show decreasing Tg values of mixtures with increasing drug loading in the 
physical mixture (Fig. 9). 
 
 
Figure 9. Tg values of Indomethacin:HPMC-AS mixtures illustrating decreasing Tg values 
with increasing mixture drug content. Tg value have been obtained by mDSC. 
The more indomethacin was present in the powder mixture, the more the mixture Tg 
approached the Tg of pure amorphous indomethacin. In this case, almost all Tg values are 
smaller than predicted Tg values by the Gordon-Taylor equation (this equation considers 
that homomolecular and hereromolecular interactions have equal strength), demonstrating 
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rather moderate or weak intermolecular interactions of indomethacin and HPMC-AS (Fig. 
10). There is one Tg experimental value which is slightly higher than the theoretical Tg, at 
30% of indomethacin in the mixture. It may be that in this particular composition, stronger 
attractive interactions between drug-polymer occur.  
 
 
Figure 10. Comparison of Indomethacin:HPMC-AS Tg values obtained from film-casted 
method (blue line) and calculated theoretical values (orange line). 
 
Indomethacin is also known for its formation of dimers (34). Thus, a polymer should be 
able to disrupt dimer-dimer interactions to prevent self-association of indomethacin 
molecules and thus decrease the crystallization tendency of an amorphous drug. The 
antiplasticization effect of HPMC-AS gradually declines until 40% of indomethacin 
content, and from this content on only changes slightly, making these mixtures prone to 
insufficient physical stability. The ability of polymer to inhibit crystallization may be 
problematic, thus problematic may also be the stabilization of amorphous indomethacin. 
Moreover, both total heat mDSC curves of 80% drug loading show the melting endotherm 
of indomethacin crystals, indicating that the solubility of the drug is exceeded in the 
polymer. Visually, the casted film was coloured by several large yellowish spots, most 
likely containing indomethacin crystals.  
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Determination of Tg values of Carvedilol/Indomethacin:Eudragit® L100-55 casted 
films 
Eudragit® L100-55 casted films with carvedilol and indomethacin were prepared using the 
film casting method described in the Materials and Methods chapter. Problems occurred 
when collecting the films from the silicone mould because they were highly brittle and 
broke into small pieces, making them difficult to collect for mDSC measurements. To 
obtain Tg values of these mixtures, another approach was chosen. Powder mixtures of 
Eudragit® L100-55 with both APIs were directly prepared in DSC pans and measured.  
The results of carvedilol mixtures do not show the same pattern as with HPMC-AS 
because three of the Tg values are higher than the Tg of pure polymer, with three of them 
being close to the polymer's Tg value (Fig. 11). All reversing mDSC curves demonstrated a 
significantly flat, poorly visible Tg with low ∆Cp (∆Cp represents the difference in the 
amount of heat between glass and super-cooled liquid, required to increase the sample's 
temperature).  
 
 
Figure 11. Tg values of Carvedilol:Eudragit® L100-55 mixtures obtained from powder 
mixtures prepared directly in DSC pans. The error bar at 60% carvedilol is missing 
because only one Tg could be determined. 
We were not successful in collecting all Tg values from the mixtures of indomethacin with 
Eudragit® L100-55 (Fig. 12). In addition, the values do not follow the pattern of 
decreasing Tg values with increased drug loading. Three values are missing because the 
reversing mDSC curves were barely readable.  
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Figure 12. Tg values of Indomethacin:Eudragit® L100-55 mixtures obtained from powder 
mixtures prepared directly in DSC pans. Three values are missing due to problematic 
determination of Tg values. 
The reason for such results is unknown. Therefore, further experiments with Eudragit® 
L100-55 were not performed and ASDs were subsequently manufactured with HPMC-AS 
only.  
 
4.2 Characterization of freshly prepared ASDs (at day 0) 
 
1. Carvedilol:HPMC-AS with 20% (w/w) carvedilol content 
 
The HME strand was uneven, transparent with a yellowish colour and many air bubbles 
captured inside the sample (Fig. 13). Transparency of the strand indicates that the particles 
in the powder mixture were melted, otherwise white dots in the strand would be observed. 
Such transparency provides confirmation that barrel temperatures were chosen correctly. 
The slightly yellow colour of the strand may be associated with the HPMC-AS due to the 
yellowish colour of pure HMPC-AS strand extruded at the end to clean the extruder from 
the API. Trapped air bubbles could be a consequence of poor degassing, air trapped in the 
pores of particles or adherent to their surfaces, or air trapped during the feeding or 
moisture present in the powder mixture evaporating during the process and then captured 
as a gas bubble in the strand (35). We kept the strand with these imperfections because the 
next step involved milling, and our final product was powder. The powder was white after 
milling. The concentration of API in ASD powder was found to be 19.8% ± 0.4% (w/w). 
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Figure 13. HME strand of Carvedilol:HPMC-
AS with 20% carvedilol content in the physical 
mixture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reversing mDSC curves showed a single Tg and no melting endotherm, confirming that 
the ASD was produced with our HME method (Fig. 14). A single Tg suggests the presence 
of a miscible system and that there is no phase separation.  
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Figure 14. Reversing heat flow from mDSC curves of two ASD replicates containing 20% 
(w/w) carvedilol measured at day 0. 
 
Tg values are slightly higher compared to values obtained from the film casting method 
(93.2 °C) and follow the positive deviation result according to the Gordon-Taylor equation. 
The average Tg value of ASD was 96.4 °C, potentially indicating that it will be stable at 
room temperature (if the Tg – 50 rule is followed). SWAXS outcomes support the fact that 
we manufactured ASD and present a picture typical for amorphous materials (Fig. 15). 
This figure illustrates an amorphous halo with no distinct peaks of a crystalline API.  
 
 
Figure 15. WAXS and SAXS analysis, respectively, of ASD of carvedilol and HPMC-AS 
with 20% (w/w) carvedilol content. Blue and green colours represent results of two 
replicates. 
 
The ATR-FTIR spectrum of ASD was compared to spectra of amorphous and crystalline 
carvedilol and HPMC-AS at room temperature. For this purpose, functional groups were 
selected which most likely participate in hydrogen bonding between the API and polymer, 
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thus both OH and carbonyl stretching regions were chosen. Crystalline and amorphous 
carvedilol differ in the OH region of the FTIR spectrum (Fig. 16). The differences in 
amorphous and crystalline IR spectra occur because material in the amorphous form has a 
different molecular arrangement, thus the IR spectrum is slightly altered. There is a clearly 
visible band centred at 3,341.8 cm
-1
 in the crystalline carvedilol spectrum, representing 
merged bands of OH and NH stretching (36). This band splits into two broad bands in the 
amorphous carvedilol spectrum and the OH band appears at 3,399.4 cm
-1
. This can be 
attributable to the breakage of intermolecular hydrogen bonding between carvedilol 
molecules existing in crystalline state. The other two lines of ASD and HPMCA-AS lack 
defined bands in this region; therefore, we may assume that hydrogen bonds were formed 
between the API and polymer, resulting in the disappearance of the free OH stretch band. 
Another possibility is that there is insufficient drug at 20% loading and therefore the OH 
stretching is not visible in the ASD spectrum.  
 
 
Figure 16. ATR-FTIR spectra in region typical for OH functional group stretching. Four 
spectra are compared: ASD with 20% (w/w) carvedilol (dark blue), amorphous carvedilol 
(red), crystalline carvedilol (black) and HPMC-AS (yellow). Spectra are displayed 
between 3,500 and 3,250 cm
-1
. 
 
All ATR-FTIR spectra were also compared in the carbonyl bond region (Fig. 17). There 
are three distinctive bands seen in the amorphous and crystalline carvedilol curves: the 
highest band at approximately 1,588 cm
-1
 is associated with NH bending vibration, with 
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the remaining two bands being the result of C=C group vibrations. These bands are slightly 
visible in the ASD spectrum; however, there is a shoulder of the C=C vibrations at around 
1,606 cm
-1
. In the carbonyl region, there is an evidence of C=O stretch and the same 
stretching is part of the HPMC-AS spectrum. The intensity of carbonyl group stretching 
decreases and widens, with a minor red shift also occurring (from 1,734.5 cm
-1
 to 1,734.4 
cm
-1
), and therefore it may be assumed that intermolecular interactions between the API 
and polymer are responsible for the observed differences. In addition, around 1700 cm
-1
, 
there is a shoulder band, which may be the hydrogen bonded C=O fraction of HPMC-AS. 
 
 
Figure 17. ATR-FTIR spectrum of ASD with 20% (w/w) carvedilol (dark blue) compared 
to spectrum of amorphous carvedilol (red), crystalline carvedilol (black) and HPMC-AS 
(yellow). The spectral region between 1,800 and 1,550 cm
-1
 is shown because it includes 
the region characteristics for carbonyl functional group stretching. 
 
2. Carvedilol:HPMC-AS with 40% (w/w) carvedilol content 
 
The appearance of an HME strand with higher carvedilol content in the powder mixture 
was identical to the lower drug loading: the strand was uneven, transparent, yellowish and 
with many bubbles (Fig. 18). The powder was white after milling. The concentration of 
API in ASD powder was found to be 40.6% ± 1.1% (w/w). 
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Figure 18. HME strand of Carvedilol:HPMC-AS with 40% (w/w) carvedilol content. 
 
All analytical techniques confirmed the successful manufacture of ASD. mDSC reversing 
curves had a single Tg and no melting point endotherm (Fig. 19). A single Tg also indicates 
that at higher drug loading, we are still dealing with a miscible system. The average Tg of 
72.5 °C indicates that the ASD has a prerequisite for being stable at room temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Reversing heat flow from mDSC curves of two ASD replicates containing 40% 
(w/w) carvedilol measured at day 0. 
 
The SWAXS method supported the mDSC data concerning amorphicity, with images 
obtained from measurement lacking any observable crystalline features (Fig. 20).  
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Figure 20. WAXS and SAXS analysis, respectively, of ASD of carvedilol and HPMC-AS 
with 40% (w/w) carvedilol content. Blue and green colours represent results of two 
replicates. 
At day 0, the ATR-FTIR spectrum of ASD with higher carvedilol loading was also 
measured and compared to pure compounds. Attention was paid to two different regions of 
the spectra: OH band and carbonyl group stretching regions (Figs. 21 and 22). In Figure 
21, there is a visible band of crystalline carvedilol which can be assigned to OH and NH 
stretching. This band is not visible in the ASD spectrum, nor is the smaller and wider 
absorption peak of the amorphous OH group, and therefore it can be assumed that these 
functional groups formed hydrogen bonds with the polymer. This state is desired because 
hydrogen bonding with the polymer helps maintain the API in an amorphous state.   
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Figure 21. ATR-FTIR spectra in region typical for OH functional group stretching. Four 
spectra are compared: ASD with 40% (w/w) carvedilol (dark blue), amorphous carvedilol 
(red), crystalline carvedilol (black) and HPMC-AS (yellow). Spectra are displayed 
between 3,450 and 3,280 cm
-1
. 
The region where carbonyl group vibrations appear shows a similar pattern to ASD with 
lower carvedilol loading. A strong band in the ASD spectrum can be observed at 1,734.9 
cm
-1
, although is not observed in spectra of pure carvedilol compounds. The band suggests 
the presence of drug-polymer interactions via hydrogen bond formation. At lower 
wavenumbers, three small bands are displayed (the almost narrow part of the ASD 
spectrum with lower carvedilol concentration) and may be a consequence of higher 
carvedilol concentration in the ASD, while their widening could suggest increased mixing 
and dispersive interaction of drug molecules with the polymer matrix.  
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Figure 22. ATR-FTIR spectrum of ASD with 40% (w/w) carvedilol (dark blue) compared 
to spectrum of amorphous carvedilol (red), crystalline carvedilol (black) and HPMC-AS 
(yellow). The spectral region between 1,800 and 1,540 cm
-1
 is provided because it includes 
the region characteristics for carbonyl functional group stretching. 
 
3. Indomethacin:HPMC-AS with 20% (w/w) indomethacin content  
 
The HME strand with indomethacin has the same visual characteristics as strands with 
carvedilol, although it has a bright yellow colour (Fig. 23). This colour is associated with 
both compounds, with the powder also remaining yellowish after milling (similarly, 
indomethacin solutions were yellow). The concentration of API in ASD powder was found 
to be 20.0% ± 0.8% (w/w).  
 
Figure 23. HME strand of Indomethacin:HPMC-AS with 20% (w/w) indomethacin 
content. 
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The mDSC shown for this ASD had a single Tg with a value of 82.1 °C. Indomethacin in 
20% (w/w) concentration is miscible with HPMC-AS and together with high Tg may 
ensure the stability of the ASD at room temperature. No melting endotherm was observed 
in the reversing mDSC curve, thus the product is expected to be amorphous (Fig. 24).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Reversing heat flow from mDSC curves of two ASD replicates containing 20% 
(w/w) indomethacin measured at day 0. 
 
SWAXS verified that the amorphous product was manufactured and did not detect any 
crystals (Fig. 25). Both curves present a halo pattern common for amorphous samples.   
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Figure 25. WAXS and SAXS analysis, respectively, of ASD of indomethacin and HPMC-
AS with 20% (w/w) indomethacin content. Blue and green colours represent results of two 
replicates. 
The ATR-FTIR spectrum was compared to spectra of amorphous and crystalline 
indomethacin, as well as to the spectrum of HPMC-AS (Fig. 26). 
 
 
Figure 26. ATR-FTIR spectrum of ASD with 20% (w/w) indomethacin (dark blue) 
compared to spectrum of amorphous indomethacin (red), crystalline indomethacin (black) 
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and HPMC-AS (yellow). The spectral region between 1,800 and 1,550 cm
-1
 is provided 
because it includes the region characteristics for carbonyl functional group stretching. 
 
Indomethacin possesses two carbonyl functional groups, one being a benzoyl group and 
the other the carbonyl group of carboxylic acid. Crystalline indomethacin (form) has two 
bands in the carbonyl region: a band at 1,688.2 cm
-1
 belonging to the benzoyl group, while 
carboxylic acid in the cyclic dimer is detected at 1,711.7 cm
-1 
(34). The spectrum of 
amorphous indomethacin shows three bands in the carbonyl region. The benzoyl band of 
amorphous indomethacin appears at 1,678.2 cm
-1
, while at 1,705 cm
-1
, the stretching of the 
cyclic dimer is detected; the third band at around 1,737 cm
-1 
is associated with non-
hydrogen-bonded acid C=O stretching vibration. The presence of cyclic dimer bands in 
amorphous and crystalline spectra indicates that indomethacin forms dimers in both forms 
of solids, although amorphous indomethacin also contains molecules which are not 
included in dimerization and non-dimerized carbonyl groups are detected at higher 
wavenumbers. The bands around 1,590 cm
-1 
are the result of indole ring vibration. 
The spectrum of ASD includes the spectral features of the amorphous form and HPMC-
AS. Bands in the ASD spectrum at 1,732.5 cm
-1
 can be assigned to C=O stretching of 
HPMC-AS, although there may also be overlapping band associated to the hydrogen 
bonded carbonyl groups of carboxylic acid associated with amorphous API with C=O 
polymer vibrations. This band is followed by a small shoulder which could be due to 
indomethacin dimer stretching, with a smaller band at 1,683.8 cm
-1
 possibly indicating 
benzoyl stretching. Stretching vibration of the cyclic dimer is minimal, therefore it can be 
suggested that ASD does not contain indomethacin dimers and that API is hydrogen 
bonded to the polymer via carboxylic acid groups (how this hydrogen-bonded band 
changes with time is illustrated in spectra from the stability study of ASD with 40% 
indomethacin). 
 
4. Indomethacin:HPMC-AS with 40% (w/w) indomethacin content 
 
The last HME strand was visually similar to the strand containing 20% (w/w) 
indomethacin: it had a bright yellow colour, with no white particles captured in the strand 
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and bubbles being present inside the product (Fig. 27). The milled powder had a yellowish 
colour. The concentration of API in ASD powder was found to be 37.9% ± 1.2% (w/w).  
 
 
Figure 27. HME strand of Indomethacin:HPMC-AS with 40% (w/w) indomethacin 
content. 
 
Results obtained from analytical methods for the HME strand with 40% (w/w) 
indomethacin varied slightly from the remaining results obtained for other HME strands. 
This variation was expected because the film-casting method demonstrated an excess 
solubility of indomethacin in HPMC-AS, resulting in yellowish parts of films representing 
immiscibility or even insolubility of the API in the polymer matrix (Fig. 28).  
                                                                         
Figure 28. Films of indomethacin and HPMC-AS in 
a silicone mould. Drug loading in the powder 
mixture is increasing from left to right. The film in 
the red circle is due to 40% (w/w) indomethacin in 
the mixture. Slightly transparent yellowish parts 
may represent phase separation of amorphous 
indomethacin from amorphous HPMC-AS, while 
the non-transparent yellowish part might contain 
crystals of indomethacin. 
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There is a single Tg in the mDSC reversing curve and small melting endotherm (Fig. 29). 
This endotherm is associated with crystalline indomethacin particles which did not 
dissolve in the polymer and melted close to the melting point of the API (the polymer 
slightly changes its melting point position (23)). The remaining indomethacin dissolved in 
the polymer matrix; this miscibility is demonstrated by the single Tg, otherwise there 
would be two separate Tg values of amorphous indomethacin and amorphous HPMC-AS.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Reversing heat flow from mDSC curves of two ASD replicates containing 40% 
(w/w) indomethacin measured at day 0. 
 
These data provide confirmation that drug loading should be taken into consideration when 
formulating an ASD. The Tg value of 50.9 °C indicates that there may be a problem with 
the stability of amorphous indomethacin at room temperature and that ASD with such low 
Tg values should be stored in a refrigerator or freezer.  
The SWAXS spectrum from day 0 does not support the DSC results regarding the presence 
of crystals because the observed baseline is typical for amorphous materials (Fig. 30). 
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Figure 30. WAXS and SAXS analysis, respectively, of ASD of indomethacin and HPMC-
AS with 40% (w/w) indomethacin content. Blue and green colours represent results of two 
replicates. 
It is known that that the ASD sample contained amorphous indomethacin, as well as 
indomethacin crystals, although there is most likely an insufficient amount of crystals in 
the sample. The X-ray beam probably passed the region with amorphous indomethacin, 
and thus SWAXS did not recognize any crystals. 
 
The ATR-FTIR spectrum of ASD has similar patterns to the spectrum at a lower drug 
loading. From Figure 31, it can be observed that the ASD spectrum includes the combined 
spectral features of amorphous indomethacin and HPMC-AS. 
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Figure 31. ATR-FTIR spectrum of ASD with 40% (w/w) indomethacin (dark blue) 
compared to spectrum of amorphous indomethacin (red), crystalline indomethacin (black) 
and HPMC-AS (yellow). The spectral region between 1,800 and 1,500 cm
-1
 is shown 
because it includes the region characteristics for carbonyl functional group stretching. 
The bands in carbonyl regions represent probable overlapping of C=O vibration of the 
polymer's carbonyl group and indomethacin's hydrogen bonded C=O, continuing with a 
slight slope with a small shoulder, which may be due to cycling dimer stretch. Following 
the curve towards lower wavenumbers, the peak at 1,680.88 cm
-1
 is associated with the 
benzoyl functional group. The cyclic dimer shoulder may be due to indomethacin dimers, 
possibly indicating that drug interactions are still not sufficiently strong, or that more 
hydrogen bonds with polymer cannot be formed, and thus only part of the API molecules 
are hydrogen bonded to the polymer. The other API molecules could be present in the 
ASD powder, but do not form ASD, and therefore they may originate from indomethacin 
crystals.  
 
4.3 Stability evaluation of ASDs 
 
All ASD powders were stored in a stability chamber at 40 °C and 75% RH and analyzed at 
time points: one week, two weeks and one month. Each powder was divided into glass 
vials — either closed with lids and parafilm or in opened glass vials.  
For stability evaluation of the samples, the same techniques were used as for day 0 and 
were measured as two replicates. mDSC was used for comparing Tg values with powders 
at day 0 (decreasing Tg values, one or two Tg values); SWAXS assisted with the evaluation 
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of amorphicity (amorphous/semi-crystalline/crystalline sample), while ATR-FTIR was 
used for observing the hydrogen bonds between APIs and polymer (shifts of bands, band 
shapes). All of the results provide information regarding the ability of the polymer to 
stabilize amorphous API, and hence the stability of ASDs. 
 
1. Carvedilol:HPMC-AS with 20% (w/w) carvedilol content 
 
The same mDSC temperature programme was used as for the samples measured at day 0. 
Reversing mDSC curves of closed and open glass vials led to similar Tg values (except one 
case, Fig. 32) to the sample from day 0. These Tg curves have a single Tg and show no 
crystallization exotherm followed by melting endotherm.  
 
 
Figure 32. Comparison of Tg values of ASD with 20% (w/w) carvedilol during stability 
study with two Tg values of ASD powder from a closed container at 1-week time point. 
The average Tg of samples from closed containers was calculated from Tg of mixtures and 
does not include single value of pure amorphous carvedilol at 1-week time point. 
Tg values vary slightly from sample to sample but do not show any particular pattern, a 
result which could be expected during a stability study: Tg values do not decrease in open 
containers due to the humid environment. The average Tg values of the samples from open 
and closed containers are comparable after one month; hence, during this time, there is no 
or negligible influence of moisture on the powders because the plasticizing effect of water 
was not observed. All samples remained amorphous during the accelerated stability study 
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and no crystalline carvedilol particles occurred (detected by mDSC as a melting endotherm 
following Tg). This result may indicate that HPMC-AS is suitable for maintaining the API 
in an amorphous state even at elevated stress conditions such as those associated with 
temperature and humidity extremes. 
 
An amorphous phase separation occurred in one of the closed samples tested after one 
week’s storage in the stability chamber. There are two separated Tg values visible, one 
close to the Tg value of pure carvedilol and the other representing the Tg of ASD at this 
composition (Fig. 33). Although the other curve revealed a single Tg, the transition 
between glassy and rubbery states is not clear and the curve has few imperfections. For this 
slightly uneven curve, a borderline merger of two Tg values can be observed, indicating 
that there may be some phase separation, but that their compositions are similar. 
 
Figure 33. mDSC plot showing reversing heat flow from the mDSC curve with two Tg 
values: Tg1 at 42.3 °C and Tg2 at 96.4 °C (marked by arrows). An amorphous phase 
separation occurred for one of the two ASD replicates with 20% (w/w) carvedilol in the 
closed glass vial after one week’s storage in the stability chamber. 
In addition, it is clear that amorphous carvedilol was produced by HME because of the 
absence of a melting peak. Compared to other results of this particular ASD, it can be 
assumed that this result may be sampling issue and that the sample for the mDSC was 
taken from the region with pure amorphous carvedilol. This is the most likely explanation 
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because it happened with the sample in a closed glass vial where the effect of moisture is 
minimal.  
To avoid such a case, for the next ASD with 40% (w/w) carvedilol, all mDSC samples for 
the stability study were prepared on day 0 (half of them closed with a pierced aluminium 
lid and put into the closed glass vial; half of them left open) and placed together with glass 
vials for the remaining analysis into the stability chamber. No similar further cases 
appeared, thus the mDSC samples of ASDs containing indomethacin were prepared at 
individual time points.  
Interactions between API and polymer were also investigated with SWAXS during the 
entire stability study. A comparison of all curves from day 0, followed by time points of 
open and closed containers, is illustrated in Figure 34.  
 
 
Figure 34. An overview of all WAXS and SAXS measurements performed during the 
stability study of ASD containing 20% (w/w) carvedilol. Colours represent results of each 
time point during the stability study. 
During the 1-month observation through characterization of ASD, there was no sample 
with clear peaks which stood out from the baseline. All spectra affirmed that ASD 
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maintained its properties through a certain period of time, irrespective of the sample 
storage conditions in the stability chamber.  
 
All spectra were compared at once using the ATR-FTIR method. Spectra are results of 
measurements provided at each time point and provide information from samples stored in 
open and closed glass vials. Attention was paid to regions displaying functional groups 
participating in hydrogen bonding. As the first, the spectra of hydroxy group vibration are 
illustrated in Figure 35.  
 
 
Figure 35. ATR-FTIR spectra of ASD with 20% (w/w) carvedilol during stability study. 
The region of OH stretching is illustrated. 
 
The samples stored in open and closed containers were compared, with higher absorbance 
in samples from open containers being observed. These samples were constantly exposed 
to humid conditions during the entire study and behind the higher intensities of these bands 
may be additional formation of hydrogen bonds with moisture. Because there is no change 
in width of the bands, it can be assumed that hydrogen bonds are present, otherwise the 
bands tend to be narrower.    
Spectra of carbonyl group vibrations are illustrated in Figure 36. 
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Figure 36. ATR-FTIR spectra of ASD with 20% (w/w) carvedilol during the stability 
study. The upper part of C=O band is shown for better visualization. 
 
If we assume that this particular band is associated with free C=O stretching of HPMC-AS, 
decreasing of the band intensity likely leads to a minor red shift occurring in samples from 
open containers. Decreasing non-hydrogen bonded functional group intensity may be due 
to the creation of new hydrogen bonds, which are associated with increased moisture 
content. New hydrogen bonds probably do not affect existing interactions of the polymer 
with API because no other changes occurred.  
 
2. Carvedilol:HPMC-AS with 40% (w/w) carvedilol content 
 
Evaluation of the samples using mDSC demonstrated stable ASD in all cases (Fig. 37). As 
mentioned previously, DSC samples were prepared on day 0 and placed into the stability 
chamber; they were then taken out for characterization at specific time points.  
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Figure 37.  Individual and average Tg values of all ASD samples with 40% (w/w) 
carvedilol at each time point during stability study. 
All reversing mDSC curves showed one Tg and samples stayed amorphous during entire 
stability study. There were no crystallization exotherms which would provide information 
regarding the presence of crystalline carvedilol, although the samples were stored at 
approximately 30 °C below their Tg (as a rule of thumb, Tg - 50 should be followed to 
avoid the risk of crystallization). No significant difference in individual and average Tg 
values was observed between samples placed in closed and open containers, and hence the 
plasticizing effect of moisture is not confirmed in this case. According to these results, it 
can be assumed that HPMC-AS is also capable of stabilizing amorphous carvedilol at 
higher concentrations.  
This assumption was also confirmed by SWAXS and ATR-FTIR results obtained during 
our observation time. In the SWAXS plots displayed in Figure 38, there are visible curves 
with a typical halo pattern for amorphous systems, with no difference occurring between 
the samples from open and closed containers.  
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Figure 38. An overview of all WAXS and SAXS measurements performed during the 
stability study of ASD containing 40% (w/w) carvedilol. Colours represent results of each 
time point during the stability study. 
The stability of the samples was also investigated by ATR-FTIR, with the same pattern in 
the OH stretching region in samples in open vials being noted. The bands from one week, 
two weeks and 1-month-old samples have higher intensity then the three samples from 
closed vials (Fig. 39). This was found to be the only difference between the samples, 
possibly due to the formation of new hydrogen bonds between moisture and powders from 
open vials.   
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Figure 39. ATR-FTIR spectra of ASD with 40% (w/w) carvedilol during the stability 
study. The region of OH stretching is illustrated. 
Comparing the position of every band characteristic for C=O vibration, it can be observed 
that bands of the samples stored in open vials are slightly shifted towards lower 
wavenumbers, a process typical for new intermolecular interactions (Fig. 40). Because 
these minor shifts are identified in bands which belong to samples from open containers, 
this shift is probably the result of the ASD's interactions with moisture.  
 
 
Figure 40. ATR-FTIR spectra of ASD with 40% (w/w) carvedilol during the stability 
study. The upper part of the C=O band is shown for better visualization. 
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3. Indomethacin:HPMC-AS with 20% (w/w) indomethacin content 
 
The solvent casting approach brought information regarding slightly weak drug-polymer 
interactions, what may affect the stability of ASD. There were no signs of instability 
observed in mDSC outcomes. Through the entire stability study, a single Tg was present, 
with no melting endotherm. Amorphous phase separation or crystallization did not occur, 
resulting in stable ASD during the 1-month observation period, as a consequence of low 
drug loading and HPMC-AS's ability to work as a stabilizer for the amorphous drug. Tg 
values are comparable between powders in open and closed containers and this result 
supports the idea of stable ASD even at higher temperature and humidity during storage 
(Fig. 41).   
  
 
Figure 41. Individual and average Tg values of all ASD samples with 20% (w/w) 
indomethacin at each time point during the stability study. 
WAXS and SAXS curves are comparable at all time points during the stability study, with 
the pattern typical for amorphous materials being similar for samples in open and closed 
glass vials (Fig. 42). Measurements did not indicate the presence of any crystals in the 
samples and support the DSC data regarding the successful polymer stabilization of 
amorphous indomethacin.  
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Figure 42. Overview of all WAXS and SAXS measurements performed during the 
stability study of ASD containing 20% (w/w) indomethacin. Colours represent results of 
each time point during the stability study. 
The carbonyl region displayed in Figure 43 shows six spectra of samples from open and 
closed containers. The band with higher intensity may represent indomethacin's carboxylic 
acid bonded to polymer, while the polymer's carbonyl group could be part of the band. 
There is a decreasing tendency in intensity of spectra from three samples stored in open 
vials. It can be assumed that the change in intensity may be the result of hydrogen bond 
disruption between API and polymer, potentially affecting the stability of ASD during its 
lifetime. 
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Figure 43. ATR-FTIR spectra of ASD with 20% (w/w) indomethacin during the stability 
study. The region of carbonyl stretching is illustrated. 
 
4. Indomethacin:HPMC-AS with 40% (w/w) indomethacin content 
 
Measurements during the stability study confirmed the outcomes from day 0 with respect 
to the ASD exceeding drug solubility. There was a melting endotherm accompanying the 
Tg in every mDSC reversing curve at 144.7 ± 0.13 °C. Tg values of samples stored in the 
open glass vials are in each time point lower than Tg values of samples in closed vials, 
potentially as a result of humidity because water can act as a plasticizer (Fig. 44). In 
addition, it is difficult to assess the Tg value of one of the samples in an open container 
from the 1-month time point, thus it is not displayed with other Tg values in Figure 44. 
The average Tg value of samples stored in open containers is calculated from values 
obtained from one and two weeks.   
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Figure 44. Individual and average Tg values of all ASD samples with 40% (w/w) 
indomethacin at each time point during the stability study. The Tg value of the sample from 
an open container at the 1-month time point is missing due to difficulties estimating the 
glass transition. 
 
All mDSC curves have few imperfections, although for one sample stored in an open glass 
vial for one week in the stability chamber, a crystallization exotherm is visible (Fig. 45).    
 
 
Figure 45. DSC plot of ASD with 40% (w/w) indomethacin content measured after one 
week of storage in an open container in the stability chamber. Glass transition, 
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crystallization exotherm and melting endotherm are observed for one of the two replicate 
samples. 
All samples were measured as two replicates, with a crystallization exotherm only 
occurring for one of the DSC samples, which was prepared from the same powder. A 
melting peak was already visible for the freshly prepared sample, therefore crystals of 
indomethacin were part of the ASD powder from the beginning. The low Tg of the ASD 
and elevated storage conditions caused formation of nuclei followed by crystal growth. 
This was an expected outcome (although clear crystallization peaks were not detected for 
other samples) due to the storage temperature, which was only approximately 11 °C above 
the ASD glass transition and high humidity. Visually, the powder was stuck into one piece 
in the vial and it had to be broken using a spatula to make the powder flow again. The Tg 
of the sample was lower (Tg = 44.9 °C) than the Tg of pure indomethacin, possibly due to 
humidity. Because the crystallization peak occurred for one of the two replicate samples, 
crystals may have been formed randomly in the powder.   
Tg values of the samples from open vials were after two weeks’ storage lower than the Tg 
value of pure indomethacin, possibly due to humidity. In both samples, the crystallization 
peak was missing. The next measurements were provided after one month, with there 
being no clear glass transitions visible from reversing curves; this information is missing in 
the plot in Figure 44.   
Comparing the results from samples stored in closed containers, all Tg values were 
collected, no crystallization exotherms were recognized and Tg values of ASD do not 
decline below the Tg of pure indomethacin but instead stay close to the day 0 value. 
Therefore, samples protected in the sealed container can maintain their characteristics even 
when kept in stress conditions for a certain period of time.  
 
Existing crystals in this particular ASD were also displayed in SWAXS curves (Fig. 46). 
They can be observed as peaks towering above the amorphous halo. Peaks appeared two 
weeks after manufacturing and comprise part of the curves of samples directly exposed to 
stress conditions: red peaks represent 2-week-old samples, while olive green peaks 1-
month-old samples. The remaining curves express characteristics typical for amorphous 
systems.  
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Figure 46. Overview of all WAXS and SAXS measurements performed during the 
stability study of ASD containing 40% (w/w) indomethacin. Colours represent results of 
each time point during the stability study. 
 
 
Figure 47. ATR-FTIR spectra of ASD with 40% (w/w) indomethacin during the stability 
study. The region of carbonyl stretching is illustrated. 
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Other methods used for stability evaluation of ASD detected the presence of indomethacin 
crystals in the samples. These results were also supported by ATR-FTIR because when 
examining the spectra of samples from open containers (blue, red and grey colour), 
similarities with the spectrum of crystalline indomethacin can be observed (see Fig. 26): 
there are two bands visible, with their intensities being higher for older samples (Fig. 47). 
Similarly, the small shoulder on the left side of the curve marked by one week decreases 
with time and becomes narrow for the 1-month-old sample. The older a sample is, the 
more hydrogen bonds break between the polymer and API as a result of moisture exposure. 
In this process, more free API (and polymer) groups are produced and indomethacin forms 
intramolecular hydrogen bonds. When such a process occurs in ASD, amorphous-
amorphous phase separation appears. 
Yellow, black and green spectra are associated with samples stored in closed containers 
and they preserve the band on the left, indicating hydrogen-bonded carboxylic acid. The 
API in these samples is still intermolecularly bonded to polymer, although bond disruption 
occurred in older samples and is displayed as a decreasing intensity of the C=O stretch and 
increasing intensity of the band typical for indomethacin dimer vibration.  
 
 
4.4 Temperature-dependent ATR-FTIR 
 
It is well known that intermolecular interactions between APIs and polymers play an 
important role in the stabilization of amorphous APIs. Stabilization is often achieved 
through formation of hydrogen bonds between the molecules of both compounds, a process 
which can be observed using IR spectroscopy. IR spectra can vary depending on ASD 
composition (chemistry of the compounds, drug loading) and the temperature at which 
measurements are performed. To maintain the stability of an amorphous API within an 
ASD, storage conditions such as temperature and humidity should be taken into 
consideration to ensure that the ASD does not lose its characteristics and transform into its 
crystalline form. When such a process begins, a change can be observed in intermolecular 
interactions between the API and polymer and as long as the interactions are hydrogen 
bonds, they can be detected in regions typical for OH or C=O stretching. To study such 
changes, ATR-FTIR measurements were made at temperatures below, at and higher than 
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the Tg of the mixtures. Detailed information regarding sample preparation and 
measurements are available in the Materials and Methods chapter. The spectra are 
displayed in the Appendix, showing the region of carbonyl functional group stretching. 
 
In situ casted films with carvedilol 
Spectra of casted films with increasing drug loading measured at the lowest temperature 
demonstrate features of the spectra of both HPMC-AS and carvedilol. The carbonyl band 
intensity of HPMC-AS decreases with higher drug loading, while the band on the right part 
of the spectra displays increasing intensity of carvedilol functional groups. The more API 
is present in the mixture, the more the patterns are similar to the pure carvedilol spectrum. 
Spectra of casted films with lower drug loading display the polymer's non-bonded carbonyl 
group as the main vibration, while spectra with higher drug loading contain clear bands of 
NH bending and carbon double bond vibrations. The position of the polymer's carbonyl 
stretch changes from 1,739.9 cm
-1
 for film with 10% (w/w) of API to 1,738.6 cm
-1
 for film 
with 80% (w/w) of API at the lowest measured temperature. The band position changes 
according to drug-polymer interactions via hydrogen bond formation, with the more bonds 
formed, the larger the red shift of the carbonyl stretch being observed.  
All casted films were heated using different temperature programmes chosen individually 
for each film and in every case, the film was heated to the mixture's Tg. The spectra display 
the same pattern — the band around 1,739/1,740 cm-1 moves towards the higher 
wavenumber as the temperature increases due to hydrogen bond disruption between 
carvedilol and HPMC-AS. In addition, the spectra often show rapid decreasing of the 
band's intensity after Tg. 
 
In situ casted films with indomethacin 
The indomethacin spectra follow a similar pattern as the spectra of carvedilol-casted films 
— as drug loading increases, API features become more present in the casted film 
spectrum. The mixture containing 10% (w/w) indomethacin has a dominant band around 
1,740 cm
-1
 due to non-bonded carbonyl stretching of HPMC-AS. Up to 50% (w/w) drug 
loading, there is a shoulder visible on the right part of the polymer's carbonyl band, 
potentially indicating the presence of part of a hydrogen bonded C=O functional group. At 
60% (w/w) indomethacin, the shoulder becomes an independent band; therefore, it is likely 
that at this drug concentration, the largest number of hydrogen bonds are present.   
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During the heating process, all spectra showed changes in hydrogen bonds between 
indomethacin and HPMC-AS, with their disruption being confirmed by a blue-shift.  
 
4.5 Enthalpy relaxation 
 
The amorphous solids are in a non-equilibrium state and during their storage at 
temperatures below Tg, they tend to recrystalize through the equilibrium line of a super-
cooled liquid due to structural relaxation. The super-cooled liquid is in an equilibrium state 
compared to the glass, but it is in a pseudo-equilibrium state in comparison with the 
crystal. Structural relaxation provides information regarding the molecular mobility and is 
characterized by the structural relaxation time  and the stretched exponential parameter , 
which can be obtained by fitting the equation of the calculated relaxation function using 
the KWW equation (see pages 6 and 7). The heat capacity values after a certain annealing 
time, Cp, were obtained from DSC measurements, together with Tg values of aged glasses. 
The enthalpic relaxation values at a specific annealing time, Hrelax, were collected from 
the difference between the integrated area of the enthalpic endotherms of aged and unaged 
samples observed in the non-reversing mDSC curves.  
ASD loses enthalpy and free volume during aging and it is expected that the change of its 
properties increases with time. This change can be observed as an endothermic band, 
which becomes larger during the aging process (Fig. 48). 
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Figure 48. Non-reversing heat flow from mDSC curves of ASD containing 20% (w/w) 
indomethacin obtained after specific aging times are used for illustration purposes. The 
curves have been shifted for presentation reasons along both axes. 
During aging, the glass loses its enthalpy; therefore, more heat is required to pass the Tg in 
the case of aged glass than for freshly prepared glass. Because the sample was aged for 
different aging times, varying amounts of heat were recorded by DSC and a common 
pattern for ASD samples can be observed: the longer the aging time, the more enthalpy is 
lost in the sample, and thus more energy is required to pass the Tg (Fig. 49, Table II). 
 
 
 
 
 
 
 
 
 
 
 
Figure 49. Recovered enthalpies as a function of time: ASD with 20% (w/w) carvedilol 
(●); ASD with 40% (w/w) carvedilol (▲); ASD with 20% (w/w) indomethacin (■); ASD 
with 40% (w/w) indomethacin (◆). 
 
The enthalpy change depends on the annealing temperature and thermal history of the glass 
(time) prior to aging. Thus, the recovered ASD enthalpies are the combination of these 
factors and are unique for each ASD because they differ with respect to aging temperatures 
and the time that passed since manufacturing. The curve alignment can be observed in both 
ASD samples containing carvedilol; therefore, there is only a small change in enthalpy lost 
between 8–12 hours aging time.  
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Table II. Recovered enthalpies of ASDs aged at different annealing temperatures. 
Time [h] ΔH [J/g] 
  ASD: 20% CAR ASD: 40% CAR ASD: 20% IND ASD: 40% IND 
1 0.86 ± 0.06 0.56 ± 0.07 0.72 ± 0.01 0.35 ± 0.01 
2 1.08 ± 0.22 0.90 ± 0.09 1.12 ± 0.03 0.75 ± 0.01 
4 1.46 ± 0.03 1.56 ± 0.09 1.35 ± 0.03 1.12 ± 0.02 
8 2.30 ± 0.21 2.11 ± 0.03 1.54 ± 0.01 1.44 ± 0.04 
12 2.38 ± 0.08 2.25 ± 0.15 1.78 ± 0.00 2.10 ± 0.01 
 
According to both lost and maximum enthalpies for each ASD, the relaxation function, , 
was calculated (Fig. 50). 
 
 
Figure 50. Overview of relaxation functions as a function of time: ASD with 20% (w/w) 
carvedilol (●); ASD with 40% (w/w) carvedilol (▲); ASD with 20% (w/w) indomethacin 
(■); ASD with 40% (w/w) indomethacin (◆). 
 
The relaxation function provides information regarding the portion of glass which has 
relaxed over time. The greater the value, the smaller the relaxation; therefore, all curves 
display a decreasing tendency with time. As the ASD is aged, a higher fraction is relaxed 
and approaches towards the super-cooled liquid line. The portion of relaxed glass did not 
change rapidly after eight hours aging time in carvedilol ASDs; therefore, it can be 
assumed that relaxation is approaching its maximum value. 
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Because the proportion of relaxed glass is known at every annealing time, the molecular 
mobility can be expressed by the structural relaxation time  and stretched exponential 
parameter  (Table III). The structural relaxation time is the average time of all 
relaxations present in the sample, while the stretched exponential parameter represents the 
distribution of relaxation times, with its value being between 0 and 1. 
 
Table III. Structural relaxation times, stretched exponential parameters and the relaxation 
time constants of ASDs. 
 
 
 
 
 
The structural relaxation time values indicate that ASD with 40% (w/w) carvedilol relaxes 
very quickly compared to other ASDs. Indomethacin ASDs possess longer average 
relaxation times compared to both carvedilol ASDs, potentially indicating a lower 
molecular mobility of indomethacin ASDs below Tg. Because this mobility is used as a 
predictor of the physical stability of an ASD, the most stable may be ASD with 20% (w/w) 
indomethacin.  
The values of stretched exponential parameter are below 1; therefore, there are more 
relaxation times within all ASDs. ASD with 20% (w/w) indomethacin have the lowest  
value, and therefore the distribution of relaxation times is wider than in all other cases. 
Rather than using  and  parameters, the relaxation time constant 

 is often used for 
evaluating the relaxation rate, an approach which reduces experimental errors. According 
to these values, ASD with 40% (w/w) carvedilol and ASD with 20% (w/w) indomethacin 
relax more quickly, indicating larger molecular mobility and hence potencial lower 
physical stability of ASDs. 
  
   [h]  

 
ASD with 20% CAR 13.7 0.85 9.3 
ASD with 40% CAR 8.7 0.65 4.1 
ASD with 20% IND 31.6 0.36 3.5 
ASD with 40% IND 20.1 0.74 9.2 
 62 
5. CONCLUSION 
 
Four ASDs were manufactured comprising carvedilol and indomethacin with HPMC-AS 
polymer and characterized as freshly manufactured powders, as well as during a 1-month 
stability study. ASDs are manufactured to contain amorphous API, which is 
thermodynamically unstable relative to the crystalline state and is prone to 
recrystallization; therefore, it is important to understand the properties of ASDs. Because it 
is desirable to maintain an ASD's characteristics during a medicine's shelf-life, stability 
studies must be performed in order to predict the ASD's behaviour during a particular time 
course. Various analytical methods were used for the evaluation of ASDs: mDSC, ATR-
FTIR, SWAXS and UV-VIS.  
Prior to ASDs being produced, mixtures of APIs with HPMC-AS and Eudragit® L100-55 
polymers with different drug loadings were evaluated. The experimentally obtained Tg 
values were compared to the calculated theoretical values and suggested favourable 
intermolecular interactions between carvedilol and HPMC-AS. Moderate or weak 
intermolecular interactions were defined for indomethacin and HPMC-AS, while 
unpredictably high Tg values were determined for Eudragit® L100-55 mixtures. Hence, 
ASDs were manufactured using only HPMC-AS as a polymeric carrier.  
Together, four ASDs were successfully produced using HME. The analytical methods 
demonstrated that carvedilol ASDs and an indomethacin ASD of 20% (w/w) drug loading 
contained amorphous API and did not change throughout the stability study. ASD with 
40% (w/w) indomethacin contained both amorphous and crystal indomethacin. In this case, 
the solubility of API in the polymer was exceeded, resulting in the presence of 
indomethacin crystals after the manufacturing process. This result is an example of the 
importance of drug loading or polymer selection because ASDs are often designed with 
high drug loadings of poorly water-soluble APIs. For stabilization of an amorphous API, it 
is important to store ASDs under a specific storage temperature and humidity, with strong 
drug-polymer interactions also being desirable. During the investigation of intermolecular 
interactions, a red shift or band broadening was observed due to hydrogen bond formation. 
In addition, the disruption of hydrogen bonds was noted after passing the Tg of the mixture, 
providing confirmation of the problematic stability of ASDs after Tg, when molecular 
movements are sufficiently fast to initiate the crystallization process. Although ASDs 
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mainly comprise only 2-component systems, they are complex, and this work has 
demonstrated the influence of polymer and drug loading on their properties.  
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7. APPENDIX 
In situ casted films with carvedilol (Chapter 3, Section 3.4) measured by TD ATR-FTIR.  
 
Spectrum 1. Spectra of casted films with increasing drug loading, showing spectral 
features of both HPMC-AS and carvedilol.  
 
 
 
 
Spectrum 2. Spectra of casted film with 10% (w/w) carvedilol content. Tg = 105.1 °C 
(dark red). 
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Spectrum 3. Spectra of casted film with 20% (w/w) carvedilol content. Tg = 92.4 °C (dark 
green). 
 
 
 
 
 
Spectrum 4. Spectra of casted film with 30% (w/w) carvedilol content. Tg = 83.1 °C (dark 
blue). 
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Spectrum 5. Spectra of casted film with 40% (w/w) carvedilol content. Tg = 80 °C (dark 
blue). 
 
 
 
 
Spectrum 6. Spectra of casted film with 50% (w/w) carvedilol content. Tg = 74.9 °C (dark 
blue). 
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Spectrum 7. Spectra of casted film with 60% (w/w) carvedilol content. Tg = 60.4 °C (dark 
blue). 
 
 
 
 
Spectrum 8. Spectra of casted film with 80% (w/w) carvedilol content. Tg = 44.3 °C (dark 
blue). 
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In situ casted films with indomethacin (Chapter 3, Section 3.4) measured by TD ATR-
FTIR.  
 
Spectrum 1. Spectra of casted films with increasing drug loading, illustrating spectral 
features of both HPMC-AS and indomethacin.  
 
 
 
 
Spectrum 2. Spectra of casted film with 10% (w/w) indomethacin content. Tg = 91.9 °C 
(dark green). 
 
 
 
  
 72 
Spectrum 3. Spectra of casted film with 20% (w/w) indomethacin content. Tg = 83.2 °C 
(dark blue). 
 
 
 
 
Spectrum 4. Spectra of casted film with 30% (w/w) indomethacin content. Tg = 70.1 °C 
(dark blue). 
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Spectrum 5. Spectra of casted film with 40% (w/w) indomethacin content. Tg = 57.8 °C 
(dark blue). 
 
 
 
 
Spectrum 6. Spectra of casted film with 50% (w/w) indomethacin content. Tg = 53.7 °C 
(dark blue). 
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Spectrum 7. Spectra of casted film with 60% (w/w) indomethacin content. Tg = 49.1 °C 
(dark blue). 
 
 
 
 
Spectrum 8. Spectra of casted film with 80% (w/w) indomethacin content. Tg = 46.6 °C 
(dark blue). 
 
 
 
 
 
 
 
